



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 870 762 A1**

(12)

**EUROPEAN PATENT APPLICATION**

published in accordance with Art. 158(3) EPC

(43) Date of publication:

14.10.1998 Bulletin 1998/42

(21) Application number: 96904324.9


(22) Date of filing: 05.03.1996

(51) Int. Cl.<sup>6</sup>: **C07C 323/59**, C07C 323/60,  
C07C 327/32, A61K 31/16,  
A61K 31/19, A61K 31/22(86) International application number:  
**PCT/JP96/00521**(87) International publication number:  
**WO 96/27585 (12.09.1996 Gazette 1996/41)**(84) Designated Contracting States:  
**CH DE FR GB IT LI**

(30) Priority: 07.03.1995 JP 46816/95

(71) Applicant:  
**SANTEN PHARMACEUTICAL CO., LTD.**  
Higashiyodogawa-ku, Osaka-shi, Osaka 533-  
8651 (JP)(72) Inventors:  
• **KAWASHIMA, Yoichi**  
Nishikyo-ku, Kyoto-shi, Tyoto 610-11 (JP)  
• **HORIUCHI, Masato**  
Settsu-shi, Osaka 566 (JP)(74) Representative:  
**Paul, Dieter-Alfred, Dipl.-Ing.**  
Fichtestrasse 18  
41464 Neuss (DE)**(54) NOVEL AMINO ACID DERIVATIVES HAVING N,N-DIALKYLAMINOPHENYL GROUP**

(57) The present invention relates to novel amino acid derivatives having an N, N-dialkylaminophenyl group represented by the general formula [I].



wherein

R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group, a lower alkanoyl group or a benzoyl group, and each phenyl ring in the phenyl-lower alkyl group and the benzoyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group;

R<sup>2</sup> represents a carboxyl group which can be converted into an ester, an amide or a hydroxamic acid;

R<sup>3</sup> represents a lower alkyl group;

R<sup>4</sup> represents a lower alkyl group;

A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group, and the phenyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group;

A<sup>2</sup> represents a lower alkylene group;

A<sup>3</sup> represents a lower alkylene group; and

"Z" represents a sulfur atom or an oxygen atom.

The compounds have inhibitory effects on LTA<sub>4</sub> hydrolase and are useful as medicines, in particular, therapeutic agents for inflammatory diseases such as rheumatic diseases, psoriasis, inflammatory intestinal diseases, gout and cystic fibrosis, in which LTB<sub>4</sub> is concerned.

**EP 0 870 762 A1****BEST AVAILABLE COPY**

**Description****TECHNICAL FILED**

5 The present invention relates to a sulfur or oxygen-containing amino acid derivative in which an N,N-dialkylaminophenyl group is introduced into a side chain, and which has inhibitory activity on leukotriene A<sub>4</sub> hydrolase, and is useful as a medicine such as an agent for treating inflammatory diseases such as rheumatic diseases, psoriasis, inflammatory intestinal diseases, gout and cystic fibrosis.

**10 BACKGROUND TECHNIQUES**

Leukotriene A<sub>4</sub> (hereinafter, abbreviated as LTA<sub>4</sub>) hydrolase, which is one of epoxide hydrolases, is a metal-containing enzyme which requires zinc in an active center.

15 LTA<sub>4</sub> hydrolase plays a catalyst-like role on biochemical conversion from LTA<sub>4</sub> into leukotriene B<sub>4</sub> (hereinafter, abbreviated as LTB<sub>4</sub>), which is a strong pro-inflammatory substance.

LTB<sub>4</sub> is arachidonic acid metabolite which is produced in 5-lipoxygenase pathway, biosynthesized in various cells including mast cell, neutrophil, monocyte, macrophage and the like, and plays a role as an important mediator in inflammation. LTB<sub>4</sub> induces chemotaxis, coagulation and degranulation of leukocyte and accumulation of polymorphonuclear leukocyte, and accelerates blood vessel permeability and edema formation. For this reason, it was reported that particularly high level of LTB<sub>4</sub> was detected in lesion parts in inflammatory diseases such as rheumatic diseases (J. Clin. Invest., 66, 116-117 (1980)), psoriasis (Br. J. Pharmacol., 83, 313-317 (1984)), inflammatory bowel diseases (Gastroenterology, 86, 453-460 (1984)) and gout (Lancet, 2, 1122-1124 (1982)) and in sputum in cystic fibrosis (Lancet, 342, 465-469 (1993)).

25 Therefore, compounds which inhibit LTA<sub>4</sub> hydrolase are expected to prevent production of LTB<sub>4</sub> and manifest therapeutic effects on inflammatory diseases.

3-Oxiranyl benzoic acid and a derivative thereof were reported to have LTA<sub>4</sub> hydrolase inhibitory activity and be useful as an agent for treating inflammatory diseases such as psoriasis, inflammatory intestinal diseases, arthritis and gout (JP-A 2-134375).

30 In addition, (+)-1-(3S, 4R)-[3-(4-phenylbenzyl)-4-hydroxychroman-7-yl]cyclopentanecarboxylic acid was reported to have LTA<sub>4</sub> hydrolase inhibitory activity and inhibit sideration of arthritis in a collagen-induced arthritis model (J. Med. Chem., 37, 3197-3199 (1994)).


On the other hand, the structural features of the present invention is in amino acid having a sulfur or oxygen atom in which the sulfur or oxygen atom is bonded with (N,N-dialkylaminophenyl)alkyl, and an amino group is bonded to a sulfur-containing acyl group. From a viewpoint of the chemical structure, the prior art will be described below.

35 Compounds in which a phenyl group is introduced on a side chain of a sulfur-containing amino acid derivative was reported to be useful as a therapeutic agent for rheumatoid diseases and a hypotensive agent (JP-A 61-165362), because the compounds have rheumatoid factor's inactivating activity and angiotensin converting enzyme inhibitory activity, and also have endopeptidase 24.11 inhibitory activity (J. Med. Chem., 37, 2461-2476 (1994)). However, a phenyl ring in amino acid side chain in the compounds described in these reports is not substituted and, thus, there is no description on compounds in which a substituent is introduced in a phenyl ring.

40 As described above, although various studies were done on sulfur-containing amino acid derivatives having a non-substituted phenyl ring on a side chain, any study has not been done yet on sulfur-containing and oxygen-containing amino acid derivatives in which an N,N-dialkylamino group is introduced on its phenyl ring. Thus, study regarding synthesis of the above compounds and study regarding their pharmacological activities, particularly, activities on LTA<sub>4</sub> hydrolase were very interesting themes.

**DISCLOSURE OF THE INVENTION**

50 The present inventors aimed at a phenyl ring on a side chain of an amino acid derivative, and performed synthesis of compounds represented by the general formula [I] which are novel amino acid derivatives with an N,N-dialkylamino group introduced on the phenyl ring and salts thereof (hereinafter, referred to as the present compound), and studied the pharmacological activity thereof. Study was made using LTA<sub>4</sub> which is a substrate for LTA<sub>4</sub> hydrolase and using as an index an amount of LTB<sub>4</sub> produced by an enzymatic reaction and, as a result, it was found that the present compound has strong inhibitory activity on LTA<sub>4</sub> hydrolase. The present compound is expected to be useful as a medicine, particularly, an agent for treating inflammatory diseases such as rheumatic diseases, psoriasis, inflammatory intestinal diseases, gout and cystic fibrosis.



wherein R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group, a lower alkanoyl group or a benzoyl group, each phenyl ring in the phenyl-lower alkyl group and the benzoyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group,

R<sup>2</sup> represents a carboxyl group which can optionally be converted into an ester, an amide or a hydroxamic acid,

R<sup>3</sup> represents a lower alkyl group,

R<sup>4</sup> represents a lower alkyl group,

A<sup>1</sup> represents a lower alkylene group optionally substituted by a phenyl group, the phenyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group,

A<sup>2</sup> represents a lower alkylene group,

A<sup>3</sup> represents a lower alkylene group, and

"Z" represents a sulfur atom or an oxygen atom, the same definitions of substituents will be used hereinafter.

The above defined groups will be described in detail. Halogen atom refers to fluorine, chlorine, bromine and iodine. Lower alkyl refers to straight or branched alkyls having 1 to 6 carbon atoms such as methyl, ethyl, propyl, hexyl, isopropyl and tert-butyl. Lower alkanoyl refers to straight or branched alkanoyls having 2 to 6 carbon atoms such as acetyl, propionyl, butyryl, hexanoyl, isobutyryl and pivaloyl. Lower alkoxy refers to straight or branched alkoxy having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, butoxy, hexyloxy, isopropoxy and tert-butoxy. Lower alkylene refers to straight or branched alkylenes having 1 to 6 carbon atoms such as methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, propylene, ethylethylene, dimethylethylene, propylethylene, isopropylethylene and methyltrimethylene.

Ester refers to esters which are widely used as a carboxylic ester, such as a lower alkyl ester such as a methyl ester, an ethyl ester, a hexyl ester, an isopropyl ester or a tert-butyl ester, and a phenyl-lower alkyl ester such as a benzyl ester. Amide refers to amides which are used as an amide of a carboxylic acid, such as an amide with ammonia, amides with a lower alkyl amine such as methylamine, dimethylamine or ethylamine, and an amide with a phenyl-lower alkylamine such as benzyl amine.

Salts in the present compound refer to any salts which are pharmaceutically acceptable and examples thereof are salts with an inorganic acid such as hydrochloric acid, nitric acid or sulfuric acid, salts with an alkali metal and alkaline earth metal such as sodium, potassium or calcium, ammonium salt, and salts with an organic amine such as diethylamine or triethanolamine. In addition, the present compound may be in the hydrate form.

By the way, in compounds applied to a medicine, the techniques are used in which compounds are converted into prodrugs such as esterification of carboxylic acid and the like for the purpose of promoting absorption and improving duration in the living body and stabilizing pharmaceutical preparations, and those derivatives are also used as preparation means, that is, as a synthetic intermediate. Therefore, also in the present invention, a carboxyl group can be converted into the form of an ester or an amide which is a conventional derivative of a carboxylic acid.

Among the present compounds, the following compounds are preferable examples.

- Compound (a) wherein, in the above general formula [I], R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group, a lower alkanoyl group or a benzoyl group, each phenyl ring in the phenyl-lower alkyl group and the benzoyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group, R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester or a phenyl-lower alkyl ester; a carboxyl group which can be converted into an amide with ammonia, a lower alkyl amine or a phenyl-lower alkyl amine or a carboxyl group which can be converted into a hydroxamic acid; each phenyl ring in the phenyl-lower alkylester and the phenyl-lower alkylamine can be substituted by a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a lower alkylendioxy group, a nitro group, an amino group, a lower alkylamino group or a lower alkanoylamino group, R<sup>3</sup> and R<sup>4</sup> each represents a lower alkyl group, A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group, the phenyl group can be substituted by a halogen atom, a lower alkyl group

or a lower alkoxy group, A<sup>2</sup> and A<sup>3</sup> each represents a lower alkylene group, and "Z" represents a sulfur atom or an oxygen atom, or salts thereof.

Among compound (a) and salts thereof, particular examples are as follows:

- 5 • Compounds and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group in compound (a).
- Compounds and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, a methyl group, a benzyl group or a benzoyl group in compound (a).
- 10 • Compounds and salts thereof wherein R<sup>1</sup> represents a hydrogen in compound (a).
- Compounds and salts thereof wherein R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester or a phenyl-lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine or a phenyl-lower alkylamine in compound (a).
- Compounds and salts thereof wherein R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine in compound (a).
- 15 • Compounds and salts thereof wherein R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester; or a carboxyl group which can be converted into an amide with methylamine in compound (a).
- Compounds and salts thereof wherein R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester in compound (a).
- 20 • Compounds and salts thereof wherein R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester in compound (a).
- Compounds and salts thereof wherein R<sup>3</sup> and R<sup>4</sup> are the same or different and each represents a methyl group or an ethyl group in compound (a).
- Compounds and salts thereof wherein A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group in compound (a).
- 25 • Compounds and salts thereof wherein A<sup>1</sup> represents a methylene group, a methylenemethylene group, an ethylene group, a propylene group, an ethylethylene group, a propylethylene group, an isopropylethylene group, a benzylethylene group, a phenylethylene group, a trimethylene group or a methyltrimethylene group in compound (a).
- Compounds and salts thereof wherein A<sup>1</sup> represents a methylene group, an ethylene group, a propylene group, an ethylethylene group, a propylethylene group, an isopropylethylene group or a phenylethylene group in compound (a).
- 30 • Compounds and salts thereof wherein "Z" represents a sulfur atom in compound (a).
- Compounds and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group, R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester or a phenyl-lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine or a phenyl-lower alkylamine in compound (a).
- 35 • Compounds and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group, R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine in compound (a).
- 40 • Compounds and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, a methyl group, a benzyl group or a benzoyl group, R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester; or a carboxyl group which can be converted into an amide with methylamine in compound (a).
- Compounds and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester, and "Z" represents a sulfur atom in compound (a).
- 45 • Compounds and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester, and "Z" represents a sulfur atom in compound (a).




Further, preferable examples of the present compound are as follows:

- 50 • Compound (b) and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group, R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester or a phenyl-lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine or a phenyl-lower alkylamine, R<sup>3</sup> and R<sup>4</sup> each represents a lower alkyl group, A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group, A<sup>2</sup> and A<sup>3</sup> each represents a lower alkylene group, "Z" represents a sulfur atom or an oxygen atom in the above general formula [I].
- 55 • Compound (c) and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group, R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine, R<sup>3</sup> and R<sup>4</sup> each represents a lower alkyl


group, A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group, A<sup>2</sup> and A<sup>3</sup> each represents a lower alkylene group, "Z" represents a sulfur atom or an oxygen atom in the above general formula [I].

- Compounds and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, a methyl group, a benzyl group or a benzoyl group, R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester; or a carboxyl group which can be converted into an amide with methylamine, R<sup>3</sup> and R<sup>4</sup> are the same or different and each represents a methyl group or an ethyl group, A<sup>1</sup> represents a methylene group, a methylmethylene group, an ethylene group, a propylene group, an ethylethylene group, a propylethylene group, an isopropylethylene group, a benzylethylene group, a phenylethylene group, a trimethylene group or a methyltrimethylene group, A<sup>2</sup> represents a methylene group or an ethylene group, and A<sup>3</sup> represents a methylene group in compound (c).
- Compound (d) and salts thereof wherein R<sup>1</sup> represents a hydrogen atom, R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester, R<sup>3</sup> and R<sup>4</sup> each represents a lower alkyl group, A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group, A<sup>2</sup> and A<sup>3</sup> each represents a lower alkylene group, and "Z" represents a sulfur atom in the above general formula [I].
- Compounds and salts thereof wherein R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester, R<sup>3</sup> represents a methyl group or an ethyl group, R<sup>4</sup> represents a methyl group or an ethyl group, A<sup>1</sup> represents a methylene group, an ethylene group, a propylene group, an ethylethylene group, a propylethylene group, an isopropylethylene group or a phenylethylene group, A<sup>2</sup> and A<sup>3</sup> both represent a methylene group in compound (d).

As an embodiment of preferable compound of the present invention, there are 3-[4-(N,N-dimethylamino)benzylthio]-2-(3-mercapto-2-methylpropionylamino)propionic acid represented by the following formula [II] and salts, an optical isomer, a diastereomer thereof, for example, (2R)-3-[4-(N,N-dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid represented by the following formula [XIII], and further (2R)-3-[4-(N,N-dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-propylpropionylamino]propionic acid represented by the following formula [XIV], and salts thereof.



A representative process for synthesizing the present compound will be described below.



wherein  $R^5$  represents a lower alkanoyl group or a benzoyl group, the phenyl ring in the benzoyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group.

$R^a$  represents an amino protecting group for amino acid.

R<sup>b</sup> represents an active ester of carboxylic acid.

X represents a halogen atom.

The above newly defined groups will be described in detail. The amino protecting group for amino acid indicates those which are widely used as a group for protecting an amino group of amino acid, such as an urethane type protecting group such as a tert-butoxycarbonyl group or a benzyloxycarbonyl group; an acyl type protecting group such as a formyl group; or an alkyl type protecting group such as a trityl group. The active ester indicates those which are widely used as an active ester of amino acid, such as a 4-nitrophenylester or an N-hydroxysuccinimidoester.

The compound represented by the above formula [III] is reacted with the compound represented by the formula [V] which is derived from the compound represented by the formula [IV] in the presence of a base to obtain the compound represented by the formula [VI], from which the amino protecting group R<sup>a</sup> is subsequently removed from the compound [VI] to obtain the compound represented by the formula [VII]. Then, the compound represented by the formula [VII] is converted into an acid halide represented by the formula [IX] or an active ester compound represented by the formula [X], and the compound [IX] or [X] is reacted with the above compound [VII] in the presence of a base to obtain the present compound (formula [XI]) wherein R<sup>1</sup> is a lower alkanoyl group or a benzoyl group (a phenyl ring thereof can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group). Then, the lower alkanoyl group, or the benzoyl group in which the phenyl ring can be substituted by the halogen atom, the lower alkyl group or the lower alkoxy group is removed from the compound [XI] in the presence of a base to obtain the present compound (formula [XII]) wherein R<sup>1</sup> is hydrogen.

Additionally, a carboxyl group in the present compound can be converted into an ester using a conventional method, if necessary. Conversely, an ester can be hydrolyzed into a carboxylic acid using a conventional method.

The compounds obtained in the above process can be converted into salts as described above according to a conventional method.

A diastereoisomer and an optical isomer are present in the compound represented by the formula [I], which are all included in the present invention. When an optically active raw material is used, a single diastereoisomer or an optical isomer is obtained. When a racemic compound is used as a raw material, various isomers can be separated by a conventional method, for example, a method using an optical resolving agent or the like.

In order to investigate the utility of the present compound, the activity of the present compound on LTA<sub>4</sub> hydrolase was studied. Study was done using as an index an amount of LTB<sub>4</sub> produced by an enzymatic reaction using LTA<sub>4</sub> as a substrate and, as a result, the present compound exhibited strong inhibitory activity on LTA<sub>4</sub> hydrolase (details will be described in the item of pharmacological experiment below). From this, the present compound is useful for a various diseases where LTB<sub>4</sub>, which is produced by an enzymatic reaction, is concerned.

The present compound can be administered orally or parenterally. Examples of dosage form are tablets, capsules, granules, powders, injections and the like. The present compound may be formulated into preparations using a conventional technique. For example, in a case of oral preparations such as tablets, capsules, granules and powders, a bulking agent such as lactose, crystalline cellulose, starch or vegetable oil, a lubricant such as magnesium stearate or talc, a binding agent such as hydroxypropylcellulose or polyvinylpyrrolidone, a disintegrating agent such as calcium carboxymethylcellulose or low-substituted hydroxypropylmethylcellulose, a coating agent such as hydroxypropylmethylcellulose, macrogol or silicone resin, and a film forming agent such as gelatin film can be added, if necessary.

Dose of the present compound can be appropriately selected depending upon symptom, age, dosage form and the like. In the case of oral preparations, dose of 0.1 to 5000 mg, preferably 1 to 1000 mg per day can be administered once or a few times.


#### PREFERRED EMBODIMENTS FOR CARRYING OUT THE INVENTION

Preparations, formulations and results of pharmacological experiment of the present compounds are shown below, and they are intended for better understanding the present invention but are not to limit the scope of the present invention.

## [Preparation]

## Reference Example 1

5 (2R)-2-tert-Butoxycarbonylamino-3-[4-(N,N-dimethylamino)benzylthio]propionic acid (Reference compound No. 1-1)



15

4-(N,N-Dimethylamino)benzylalcohol (2.0 g) is dissolved in 47% hydrobromic acid (13.5 ml), and the solution is stirred at 120-130°C for two hours and 30 minutes in a sealed tube. The reaction solution is concentrated under reduced pressure to obtain an oil. Then, a 5% aqueous citric acid solution (30 ml) is added to N-tert-butoxycarbonyl-L-cystein-  
 20 edicyclohexylamine salt (2.42 g), and the whole is extracted with methylene chloride (30 ml). The organic layer is washed with a saturated sodium chloride solution and dried over anhydrous sodium sulfate to obtain a solution of N-tert-butoxycarbonyl-L-cysteine in methylene chloride. To this solution is added N,N-diisopropylethylamine (4.7 ml) under ice-cooling, the mixture is added to the previously obtained oil while stirring, and stirring is continued at room temperature for two hours and 30 minutes. The reaction solution is concentrated under reduced pressure to distill methy-  
 25 lene chloride off, a 5% aqueous citric acid solution is added thereto, and the whole is extracted with ethyl acetate. The organic layer is washed with a 5% aqueous citric acid solution then a saturated solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting oil is purified by silica gel column chromatography to obtain 1.32 g (62.0%) of the titled compound.

30 Optical isomer of Reference compound No. 1-9

$[\alpha]_D^{20} -29.8^\circ$  (c=1.0, methanol)  
 IR (Film,  $\text{cm}^{-1}$ ) 3415, 2978, 1711, 1613, 1520, 1246, 1166, 1050

35 The following compounds are obtained by a method similar to Reference Example 1.

- (2R)-2-tert-Butoxycarbonylamino-3-[4-(N-ethyl-N-methylamino)benzylthio]propionic acid (Reference compound No. 1-2)
- (2R)-2-tert-Butoxycarbonylamino-3-[4-(N-isopropyl-N-methylamino)benzylthio]propionic acid (Reference com-  
 40 pound No. 1-3)
- (2R)-2-tert-Butoxycarbonylamino-3-[4-(N-tert-butyl-N-methylamino)benzylthio]propionic acid (Reference com-  
 pound No. 1-4)
- (2R)-2-tert-Butoxycarbonylamino-3-[4-(N,N-diethylamino) benzylthio]propionic acid (Reference compound No. 1-5)

45  $[\alpha]_D^{20} -26.6^\circ$  (c=0.47, methanol)  
 IR (Film,  $\text{cm}^{-1}$ ) 3428, 2976, 1710, 1612, 1519, 1368, 1167, 1056, 755

- (2S)-2-tert-Butoxycarbonylamino-4-[4-(N,N-dimethylamino) benzylthio]butyric acid (Reference compound No. 1-6)

50  $[\alpha]_D^{20} -9.5^\circ$  (c=0.34, methanol)  
 IR (Film,  $\text{cm}^{-1}$ ) 3325, 2976, 2930, 1709, 1520, 1227, 1165, 1050

- (2S)-2-tert-Butoxycarbonylamino-6-[4-(N,N-dimethylamino) benzylthio]hexanoic acid (Reference compound No. 1-  
 7)
- 55 • (2R)-2-tert-Butoxycarbonylamino-3-[3-(N,N-dimethylamino) benzylthio]propionic acid (Reference compound No. 1-  
 8)

$[\alpha]_D^{20} -38.5^\circ$  (c=0.48, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3332, 1709, 1580, 1392, 1337, 1246

- (2S)-2-tert-Butoxycarbonylamino-3-[4-(N,N-dimethylamino) benzythio]propionic acid (Reference compound No. 1-9)


Optical isomer of Reference compound No. 1-1

$[\alpha]_D^{20} +34.1^\circ$  ( $c=1.0$ , methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3322, 2977, 2930, 1713, 1613, 1520, 1392, 1246, 1165, 1056

#### Reference Example 2

(2S)-2-tert-Butoxycarbonylamino-3-[4-(N,N-dimethylamino) benzyloxy]propionic acid (Reference compound No. 2-1)



4-(N,N-Dimethylamino)benzylalcohol (1.62 g) is dissolved in 47% hydrobromic acid (11.1 ml), and the solution is stirred at 120-130°C for one hour and 30 minutes in a sealed tube. The reaction solution is concentrated under reduced pressure to obtain an oil. Then, a solution of N-tert-butoxycarbonyl-L-serine (2 g) in dimethylformamide (10 ml) is added dropwise to a suspension of 60% sodium hydride in dimethylformamide (10 ml) under ice-cooling, and the mixture is further stirred for 40 minutes. After the mixture is added to the previously obtained oil while stirring, the mixture is stirred at room temperature for one hour and 30 minutes. To the reaction solution is added N,N-diisopropylethylamine (1.68 ml), followed by further stirring at room temperature for two days. The reaction solution is concentrated under reduced pressure, and an aqueous saturated sodium hydrogencarbonate solution is added thereto. The mixture is washed with diethyl ether. The aqueous layer is acidified by the addition of a 10% aqueous citric acid solution and extracted with diethyl ether. The organic layer is washed with a saturated sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The resulting oil is purified by silica gel column chromatography to obtain 240 mg (7.3%) of the titled compound.

Optical isomer of Reference compound No. 2-7

IR (Film,  $\text{cm}^{-1}$ ) 3648, 3433, 1708, 1520, 1165, 1059


The following compounds are obtained by a method similar to Reference Example 2.

- (2S)-2-tert-Butoxycarbonylamino-3-[4-(N-ethyl-N-methylamino)benzyloxy]propionic acid (Reference compound No. 2-2)
- (2S)-2-tert-Butoxycarbonylamino-3-[4-(N,N-diethylamino) benzyloxy]propionic acid (Reference compound No. 2-3)
- (2S)-2-tert-Butoxycarbonylamino-4-[4-(N,N-dimethylamino) benzyloxy]butyric acid (Reference compound No. 2-4)
- (2S)-2-tert-Butoxycarbonylamino-6-[4-(N,N-dimethylamino) benzyloxy]hexanoic acid (Reference compound No. 2-5)
- (2S)-2-tert-Butoxycarbonylamino-3-[3-(N,N-dimethylamino) benzyloxy]propionic acid (Reference compound No. 2-6)
- (2R)-2-tert-Butoxycarbonylamino-3-[4-(N,N-dimethylamino) benzyloxy]propionic acid (Reference compound No. 2-7)

Optical isomer of Reference compound No. 2-1

### Reference Example 3

5 (2R)-2-Amino-3-[4-(N,N-dimethylamino)benzylthio]propionic acid dihydrochloride (Reference compound No. 3-1)



15

Under ice-cooling, anisole (613  $\mu\text{l}$ ) and 4N hydrochloric acid/dioxane (10 ml) are added to (2R)-2-tert-butoxycarbonylamino-3-[4-(N,N-dimethylamino)benzylthio] propionic acid (Reference compound No. 1-1, 1.0 g), and the mixture is stirred at room temperature for one hour. The reaction solution is concentrated under reduced pressure, and the resulting oil is washed with diethyl ether to obtain 0.84 g (91.0%) of the titled compound.

20

Optical isomer of Reference compound No. 3-14

25  $[\alpha]_D^{20} -19.6^\circ$  (c=1.0, methanol)  
IR (Film,  $\text{cm}^{-1}$ ) 3397, 2906, 1966, 1741, 1606

The following compounds are obtained by a method similar to Reference Example 3.

- 30 • (2R)-2-Amino-3-[4-(N-ethyl-N-methylamino)benzylthio] propionic acid dihydrochloride (Reference compound No. 3-2)
- (2R)-2-Amino-3-[4-(N-isopropyl-N-methylamino)benzylthio] propionic acid dihydrochloride (Reference compound No. 3-3)
- (2R)-2-Amino-3-[4-(N-tert-butyl-N-methylamino)benzylthio] propionic acid dihydrochloride (Reference compound No. 3-4)
- 35 • (2R)-2-Amino-3-[4-(N,N-diethylamino)benzylthio]propionic acid dihydrochloride (Reference compound No. 3-5)
- (2S)-2-Amino-4-[4-(N,N-dimethylamino)benzylthio]butyric acid dihydrochloride (Reference compound No. 3-6)

40  $[\alpha]_D^{20} +13.6^\circ$  (c=0.53, methanol)  
IR (KBr,  $\text{cm}^{-1}$ ) 2920, 2023, 1735, 1604, 1510, 1204, 1131

- (2S)-2-Amino-6-[4-(N,N-dimethylamino)benzylthio]hexanoic acid dihydrochloride (Reference compound No. 3-7)
- (2S)-2-Amino-3-[4-(N,N-dimethylamino)benzyloxy]propionic acid dihydrochloride (Reference compound No. 3-8)

Optical isomer of Reference compound No. 3-16

- 45
- (2S)-2-Amino-3-[4-(N-ethyl-N-methylamino)benzyloxy] propionic acid dihydrochloride (Reference compound No. 3-9)
  - (2S)-2-Amino-3-[4-(N,N-diethylamino)benzyloxy]propionic acid dihydrochloride (Reference compound No. 3-10)
  - (2S)-2-Amino-4-[4-(N,N-dimethylamino)benzyloxy]butyric acid dihydrochloride (Reference compound No. 3-11)
  - 50 • (2S)-2-Amino-6-[4-(N,N-dimethylamino)benzyloxy]hexanoic acid dihydrochloride (Reference compound No. 3-12)
  - (2R)-2-Amino-3-[3-(N,N-dimethylamino)benzylthio]propionic acid dihydrochloride (Reference compound No. 3-13)

55  $[\alpha]_D^{20} -32.1^\circ$  (c=0.52, methanol)  
IR (KBr,  $\text{cm}^{-1}$ ) 3408, 2858, 1743, 1595, 1502

- (2S)-2-Amino-3-[4-(N,N-dimethylamino)benzylthio]propionic acid (Reference compound No. 3-14)

$[\alpha]_D^{20} +18.3^\circ$  (c=1.0, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3410, 2917, 2003, 1739, 1616, 1324


Optical isomer of Reference compound No. 3-1

- 5 • (2R)-2-Amino-3-[3-(N,N-dimethylamino)benzyloxy]propionic acid (Reference compound No. 3-15)
- (2S)-2-Amino-3-[4-(N,N-dimethylamino)benzyloxy]propionic acid (Reference compound No. 3-16)

Optical isomer of Reference compound No. 3-8

#### 10 Reference Example 4

(2S)-3-Benzoylthio-2-methylpropionyl chloride (Reference compound No. 4-1)



20


Thionyl chloride (5.69 ml) is added to (2S)-3-benzoylthio-2-methylpropionic acid (13.5 g) under ice-cooling, and the mixture is stirred at room temperature overnight. The reaction solution is concentrated under reduced pressure to obtain 15 g (quantitative) of the titled compound.

25

IR (Film,  $\text{cm}^{-1}$ ) 1786, 1668, 1448, 1209, 1177

#### Reference Example 5

#### 30 4-Nitrophenyl (2S)-3-benzoylthio-2-methylpropionate (Reference compound No. 5-1)



40

To a solution of (2S)-3-benzoylthio-2-methylpropionic acid (15 g) in methylene chloride (100 ml) are successively added 4-nitrophenol (10.2 g) and dicyclohexylcarbodiimide (15.2 g) under ice-cooling, and the mixture is stirred under ice-cooling for 30 minutes and at room temperature for four hours and 30 minutes. The resulting precipitates are filtered out, and the filtrate is concentrated under reduced pressure. The resulting oil is purified by silica gel column chromatography to obtain 26.01 g (quantitative) of the titled compound.

45

An optical isomer of Reference compound No. 5-8

50

mp 42.0-44.0°C

$[\alpha]_D^{20}$  -101.2° (c=1.0, methanol)

IR (KBr,  $\text{cm}^{-1}$ ) 3079, 2988, 1759, 1660, 1592, 1521, 1351, 1323, 1204

The following compounds are obtained by a method similar to Reference Example 5.

55

- 4-Nitrophenyl benzoylthioacetate (Reference compound No. 5-2)

mp 87.0-88.2°C

IR (KBr,  $\text{cm}^{-1}$ ) 3082, 2929, 1769, 1659, 1523, 1346, 1210, 1129, 918, 687

- 4-Nitrophenyl 3-benzoylthiopropionate (Reference compound No. 5-3)

5 mp 79.2-80.5°C  
IR (KBr,  $\text{cm}^{-1}$ ) 3114, 3089, 1765, 1665, 1523, 1347, 1204, 1124, 908, 689

- 4-Nitrophenyl 6-benzoylthiohexanate (Reference compound No. 5-4)
- 4-Nitrophenyl 3-benzoylthio-2,2-dimethylpropionate

10 (Reference compound No. 5-5)

- 4-Nitrophenyl (2S)-2-benzoylthiopropionate (Reference compound No. 5-6)

15 Optical isomer of Reference compound No. 5-7

$[\alpha]_D^{20} -78.3^\circ$  (c=1.1, chloroform)  
IR (Film,  $\text{cm}^{-1}$ ) 3084, 2858, 1767, 1523, 1348

- 20 • 4-Nitrophenyl (2R)-2-benzoylthiopropionate (Reference compound No. 5-7)

Optical isomer of Reference compound No. 5-6

25  $[\alpha]_D^{20} +43.9^\circ$  (c=1.1, chloroform)  
IR (Film,  $\text{cm}^{-1}$ ) 3084, 2857, 1765, 1711, 1524, 1347

- 4-Nitrophenyl (2RS)-3-benzoylthio-2-methylpropionate (Reference compound No. 5-8)

30 mp 40.5-42.0°C  
IR (KBr,  $\text{cm}^{-1}$ ) 3076, 2979, 1758, 1661, 1593, 1522, 1346, 1209

- 4-Nitrophenyl (2RS)-3-benzoylthio-2-ethylpropionate (Reference compound No. 5-9)

35 IR (Film,  $\text{cm}^{-1}$ ) 2967, 2935, 2116, 1761, 1664, 1523, 1347, 1209, 1103, 913, 688

- 4-Nitrophenyl (2RS)-3-benzoylthio-2-propylpropionate (Reference compound No. 5-10)

IR (Film,  $\text{cm}^{-1}$ ) 3084, 1761, 1666, 1616, 1524, 1347

- 40 • 4-Nitrophenyl (2RS)-3-benzoylthio-2-isopropylpropionate (Reference compound No. 5-11)

IR (Film,  $\text{cm}^{-1}$ ) 3083, 1758, 1665, 1616, 1524, 1347, 1315

- 4-Nitrophenyl (2RS)-3-benzoylthio-2-benzylpropionate (Reference compound No. 5-12)

45 IR (Film,  $\text{cm}^{-1}$ ) 2930, 2117, 1761, 1666, 1593, 1524, 1490, 1347, 1207, 1124, 911, 689

- 4-Nitrophenyl (2RS)-3-benzoylthio-2-phenethylpropionate (Reference compound No. 5-13)

50 mp 93.8-96.0°C  
IR (KBr,  $\text{cm}^{-1}$ ) 3023, 2932, 1755, 1661, 1522, 1490, 1347, 1205, 1188, 914, 687

- 4-Nitrophenyl (3RS)-3-benzoylthiobutyrate (Reference compound No. 5-14)

55 mp 90.5-93.2°C  
IR (KBr,  $\text{cm}^{-1}$ ) 3077, 1763, 1658, 1520, 1461, 1382

- 4-Nitrophenyl 4-benzoylthiobutyrate (Reference compound No. 5-15)

mp 104.0-106.5°C


IR (KBr, cm<sup>-1</sup>) 3327, 2934, 1766, 1645, 1521, 1358, 1219, 1122, 928, 694

- 4-Nitrophenyl (2R)-4-benzoylthio-2-methylbutyrate (Reference compound No. 5-16)

IR (Film, cm<sup>-1</sup>) 2936, 1760, 1661, 1524, 1347, 1208, 1129, 912, 689

## Reference Example 6

- 10 (2R)-2-tert-Butoxycarbonylamino-3-[4-(N,N-dimethylamino)benzylthio]propionic acid methyl amide (Reference compound No. 6-1)



25 A solution of N-methylmorpholine (0.217 ml) and isobutyl chloroformate (0.256 ml) in tetrahydrofuran (5 ml) is added to a solution of (2R)-2-tert-butoxycarbonylamino-3-[4-(N,N-dimethylamino)benzylthio]propionic acid (Reference compound No. 1-1, 700 mg) in tetrahydrofuran (15 ml) under nitrogen atmosphere and under cryogen (ice-sodium chloride)-cooling, and the mixture is stirred for 15 minutes. Then, a 40% aqueous N-methylamine solution (0.756 ml) is added thereto under cryogen (ice-sodium chloride)-cooling, and the mixture is further stirred for two hours. To the reaction solution is added a 5% aqueous sodium hydrogencarbonate solution, and the mixture is extracted with ethyl acetate. The organic layer is washed with a saturated sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The resulting oil is purified by silica gel column chromatography to obtain 213 mg (29.4%) of the titled compound.

mp 96.0-104.0°C


[α]<sub>D</sub><sup>20</sup> -10.3° (c=0.47, methanol)IR (KBr, cm<sup>-1</sup>) 3340, 3078, 1685, 1552, 1391, 1365, 1242

The following compound is obtained by a method similar to Reference Example 6.

- (2R)-2-tert-Butoxycarbonylamino-3-[4-(N,N-dimethylamino)benzylthio]propionic acid benzyl amide (Reference compound No. 6-2)

## Example 1

- 45 (2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N,N-dimethylamino)benzylthio]propionic acid (Compound No. 1-1) and (2S)-2-[(2S)-3-benzoylthio-2-methylpropionylamino]-3-[4-(N,N-dimethylamino)benzylthio]propionic acid (Compound No. 1-2)



(2S)-3-Benzoylthio-2-methylpropionyl chloride (Reference compound No. 4-1, 888 mg) is added to a solution of

(2R)-2-amino-3-[4-(N,N-dimethylamino)benzylthio]propionic acid dihydrochloride (Reference compound No. 3-1, 800 mg) in a mixed solution of 1 N aqueous sodium hydroxide solution (9.76 ml)-water (16 ml) under ice-cooling, and the mixture is stirred under ice-cooling for one hour and further at room temperature for two hours and 30 minutes. The reaction solution is acidified by the addition of acetic acid and extracted with ethyl acetate. The organic layer is washed with a 5% aqueous citric acid solution then with a saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting oil is purified by silica gel column chromatography to obtain 147.7 mg (Compound No. 1-1, 13.2%) and 184.2 mg (Compound No. 1-2, 16.4%), respectively.

- (2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N,N-dimethylamino)benzylthio]propionic acid (Compound No. 1-1)

Diastereoisomer of Compound No. 1-2 and Compound No. 2-33

mp 118.0-119.4°C

$[\alpha]_D^{20}$  -134.8° (c=0.53, methanol)

IR (KBr,  $\text{cm}^{-1}$ ) 3343, 2957, 2936, 2466, 1725, 1675, 1642, 1515, 1310, 1213, 1199, 1000

- (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N,N-dimethylamino)benzylthio]propionic acid (Compound No. 1-2)

Diastereoisomer of Compound No. 1-1 and enantiomer of Compound No. 2-33


mp 93.5-97.5°C

$[\alpha]_D^{20}$  -12.5° (c=1.0, methanol)

IR (KBr,  $\text{cm}^{-1}$ ) 3351, 2977, 2933, 1712, 1658, 1515, 1203

#### Example 2

(2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N,N-dimethylamino)benzylthio]propionic acid (Compound No. 2-1, identical with Compound No. 1-1)



Triethylamine (15.3 ml) is added to a solution of (2R)-2-amino-3-[4-(N,N-dimethylamino)benzylthio]propionic acid dihydrochloride (Reference compound No. 3-1, 18 g) in a mixed solvent of methylene chloride (500 ml) and N,N-dimethylformamide (100 ml) under ice-cooling and the mixture is stirred. To the reaction mixture is added a solution of 4-nitrophenyl (2S)-3-benzoylthio-2-methylpropionate (Reference compound No. 5-1, 18.2 g) in methylene chloride (100 ml) and the mixture is stirred. Triethylamine is added to the reaction mixture to adjust the mixture to pH 9 and stirring is further continued at room temperature for five days. The reaction mixture is adjusted to pH 3 by adding acetic acid and the whole is extracted with ethyl acetate. The organic layer is washed with a 5% aqueous citric acid solution, water and a saturated sodium chloride solution successively, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained oily residue is purified by silica gel column chromatography to give 9.28 g (36.7%) of the titled compound. Physical properties of the obtained compound are identical with those of the compound No. 1-1 obtained in Example 1.

The following compounds are obtained by a method similar to Example 2.

- (2R)-2-Benzoylthioacetyl-amino-3-[4-(N,N-dimethylamino)benzylthio]propionic acid (Compound No. 2-2)

$[\alpha]_D^{20}$  -37.8° (c=0.53, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 2919, 1730, 1666, 1521, 1209, 914, 754, 689

- (2R)-2-(3-Benzoylthiopropionylamino)-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-3)

5 mp 98.0-103.0°C  
 $[\alpha]_D^{20}$  -66.1° (c=0.49, methanol)  
 IR (KBr,  $\text{cm}^{-1}$ ) 3344, 1662, 1517, 1403, 1204, 914, 686

- (2R)-2-(6-Benzoylthiohexanoylamino)-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-4)
- 10 • (2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N-ethyl-N-methylamino)benzylthio]propionic acid (Compound No. 2-5)
- (2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N-isopropyl-N-methylamino)benzylthio]propionic acid (Compound No. 2-6)
- (2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N-tert-butyl-N-methylamino)benzylthio]propionic acid (Compound No. 2-7)
- 15 • (2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N, N-diethylamino)benzylthio]propionic acid (Compound No. 2-8)

$[\alpha]_D^{20}$  -122.0° (c=0.45, methanol)  
 20 IR (Film,  $\text{cm}^{-1}$ ) 3306, 2973, 1661, 1612, 1519, 1208, 914, 755, 690

- (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-4-[4-(N, N-dimethylamino)benzylthio]butyric acid (Compound No. 2-9)

25  $[\alpha]_D^{20}$  -81.6° (c=0.51, methanol)  
 IR (Film,  $\text{cm}^{-1}$ ) 3306, 2931, 1733, 1662, 1521, 1447, 1350, 1208

- (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-6-[4-(N, N-dimethylamino)benzylthio]hexanoic acid (Compound No. 2-10)
- 30 • (2R)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-11)
- (2R)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-3-[4-(N-ethyl-N-methylamino)benzylthio]propionic acid (Compound No. 2-12)
- (2R)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-3-[4-(N-isopropyl-N-methylamino)benzylthio]propionic acid (Compound No. 2-13)
- 35 • (2R)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-3-[4-(N-tert-butyl-N-methylamino)benzylthio]propionic acid (Compound No. 2-14)
- (2R)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-3-[4-(N, N-diethylamino)benzylthio]propionic acid (Compound No. 2-15)
- 40 • (2S)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-4-[4-(N, N-dimethylamino)benzylthio]butyric acid (Compound No. 2-16)
- (2S)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-6-[4-(N, N-dimethylamino)benzylthio]hexanoic acid (Compound No. 2-17)
- (2S)-2-Benzoylthioacetylaminio)-3-[4-(N, N-dimethylamino)benzyloxy]propionic acid (Compound No. 2-18)
- 45 • (2S)-2-(3-Benzoylthiopropionylamino)-3-[4-(N, N-dimethylamino)benzyloxy]propionic acid (Compound No. 2-19)
- (2S)-2-(6-Benzoylthiohexanoylamino)-3-[4-(N, N-dimethylamino)benzyloxy]propionic acid (Compound No. 2-20)
- (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N, N-dimethylamino)benzyloxy]propionic acid (Compound No. 2-21)

- 50 Diastereo isomer of compound No. 2-46

$[\alpha]_D^{20}$  -34.4° (c=0.39, methanol)  
 IR (Film,  $\text{cm}^{-1}$ ) 3305, 2339, 1732, 1661, 1208, 1100

- 55 • (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N-ethyl-N-methylamino)benzyloxy]propionic acid (Compound No. 2-22)
- (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N, N-diethylamino)benzyloxy]propionic acid (Compound No. 2-23)

- (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-4-[4-(N, N-dimethylamino)benzyloxy]butyric acid (Compound No. 2-24)
- (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-6-[4-(N, N-dimethylamino)benzyloxy]hexanoic acid (Compound No. 2-25)
- 5 • (2S)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-3-[4-(N, N-dimethylamino)benzyloxy]propionic acid (Compound No. 2-26)
- (2S)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-3-[4-(N-ethyl-N-methylamino)benzyloxy]propionic acid (Compound No. 2-27)
- 10 • (2S)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-3-[4-(N, N-diethylamino)benzyloxy]propionic acid (Compound No. 2-28)
- (2S)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-4-[4-(N, N-dimethylamino)benzyloxy]butyric acid (Compound No. 2-29)
- (2S)-2-(3-Benzoylthio-2, 2-dimethylpropionylamino)-6-[4-(N, N-dimethylamino)benzyloxy]hexanoic acid (Compound No. 2-30)
- 15 • (2R)-2-[(2S)-2-Benzoylthiopropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-31)

Diastereo isomer of compound No. 2-32

- 20  $[\alpha]_D^{20}$  -97.9° (c=0.19, methanol)  
IR (Film,  $\text{cm}^{-1}$ ) 3367, 2930, 1730, 1662, 1581, 1447
- (2R)-2-[(2R)-2-Benzoylthiopropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-32)
- 25 Diastereo isomer of compound No. 2-31  
 $[\alpha]_D^{20}$  +6.5° (c=1.0, methanol)  
IR (Film,  $\text{cm}^{-1}$ ) 3338, 2929, 1731, 1661, 1581, 1447
- 30 • (2R)-2-[(2R)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-33)

Diastereo isomer of compound No. 1-1 and enantiomer of compound No. 1-2

- 35 mp 93.5-95.5°C  
 $[\alpha]_D^{20}$  +8.7° (c=0.49, methanol)  
IR (KBr,  $\text{cm}^{-1}$ ) 3351, 2978, 2933, 1710, 1658, 1515, 1203
- 40 • (2R)-2-[(2R)-3-Benzoylthio-2-ethylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-34)  
  
IR (Film,  $\text{cm}^{-1}$ ) 3307, 2964, 2932, 1732, 1661, 1612, 1581, 1208, 914, 755, 690
- 45 • (2R)-2-[(2R)-3-Benzoylthio-2-propylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-35)  
  
IR (Film,  $\text{cm}^{-1}$ ) 3327, 2957, 2930, 1731, 1662, 1613, 1581, 1521, 1350
- 50 • (2R)-2-[(2R)-3-Benzoylthio-2-isopropylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-36)  
  
IR (Film,  $\text{cm}^{-1}$ ) 3307, 1731, 1660, 1521, 1350, 1208
- 55 • (2R)-2-[(2R)-3-Benzoylthio-2-benzylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-37)  
  
IR (Film,  $\text{cm}^{-1}$ ) 3306, 2921, 1732, 1661, 1521, 1207, 912, 752, 687

- (2R)-2-[(2RS)-3-Benzoylthio-2-phenethylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-38)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2924, 1733, 1661, 1612, 1521, 1448, 1207, 913, 752, 689

5

- (2R)-2-[(3RS)-3-Benzoylthiobutylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-39)

IR (Film,  $\text{cm}^{-1}$ ) 3305, 2924, 1728, 1660, 1614, 1521, 1447, 1210

10

- (2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[3-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-40)

$[\alpha]_D^{20} -10.5^\circ$  (c=0.49, methanol)

15

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2971, 1732, 1661, 1580, 1448

- (2R)-2-(4-Benzoylthiobutylamino)-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-41)

$[\alpha]_D^{20} -44.0^\circ$  (c=0.57, methanol)

20

IR (Film,  $\text{cm}^{-1}$ ) 3326, 2924, 1730, 1660, 1612, 1521, 1208, 914, 755, 690

- (2R)-2-[(2S or 2R)-4-Benzoylthio-2-methylbutylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-42)

25 Diastereo isomer of compound No. 2-43

$[\alpha]_D^{20} -15.0^\circ$  (c=0.25, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3308, 2930, 1732, 1660, 1521, 1209, 913, 755, 690

- 30 • (2R)-2-[(2R or 2S)-4-Benzoylthio-2-methylbutylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-43)

Diastereo isomer of compound No. 2-42

35  $[\alpha]_D^{20} -66.5^\circ$  (c=0.25, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2931, 1731, 1660, 1521, 1208, 913, 754, 690

- (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 2-44, identical with compound No. 1-2)
- 40 • (2S)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[3-(N, N-dimethylamino)benzyloxy]propionic acid (Compound No. 2-45)
- (2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N, N-dimethylamino)benzyloxy]propionic acid (Compound No. 2-46)


45 Diastereo isomer of compound No. 2-21

### Example 3

(2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-1)

50

55



A 28% aqueous ammonia solution (91 ml) is added to (2R)-2-[(2S)-3-benzoylthio-2-methylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 1-1, 9.1 g) and the mixture is stirred at room temperature for one hour. The reaction mixture is concentrated under reduced pressure to remove ammonia and the obtained aqueous solution is washed with ethyl acetate. Next the reaction mixture is adjusted to pH 4 by adding acetic acid and the whole is extracted with ethyl acetate. The organic layer is washed with a saturated sodium chloride solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained oily residue is purified by silica gel column chromatography to give 5.75 g (81.4%) of the titled compound.

Diastereo isomer of compound Nos. 3-2 and 3-35

mp 104.4-105.8°C

$[\alpha]_D^{20} -73.7^\circ$  (c=1.0, methanol)

IR (KBr,  $\text{cm}^{-1}$ ) 3362, 2966, 2929, 2900, 2542, 1707, 1644, 1523, 1217

The following compounds are obtained by a method similar to Example 3.

- (2S)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-2)

Diastereo isomer of compound No. 3-1 and enantiomer of compound No. 3-35

mp 89.5-91.5°C

$[\alpha]_D^{20} +42.2^\circ$  (c=0.47, methanol)

IR (KBr,  $\text{cm}^{-1}$ ) 3369, 2976, 2930, 2552, 1709, 1651, 1515, 1455, 1347

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-mercaptoacetylaminopropionic acid (Compound No. 3-3)

$[\alpha]_D^{20} -35.3^\circ$  (c=0.55, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3305, 2919, 1728, 1651, 1612, 1521, 1349, 1218, 754

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-(3-mercaptopropionylamino)propionic acid (Compound No. 3-4)

$[\alpha]_D^{20} -56.5^\circ$  (c=0.50, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3305, 2918, 1728, 1650, 1612, 1521, 1350, 1217, 753

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-(6-mercaptohexanoylamino)propionic acid (Compound No. 3-5)
- (2R)-3-[4-(N-Ethyl-N-methylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-6)
- (2R)-3-[4-(N-Isopropyl-N-methylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-7)
- (2R)-3-[4-(N-tert-Butyl-N-methylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-8)
- (2R)-3-[4-(N, N-Diethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-9)

$[\alpha]_D^{20} -54.0^\circ$  (c=0.54, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3307, 2972, 1654, 1612, 1519, 1399, 1267, 1196, 1154, 816, 666

- (2S)-4-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]butyric acid (Compound No. 3-10)

mp 111.5-115.0°C  
 5  $[\alpha]_D^{20}$  -36.2° (c=0.49, methanol)  
 IR (KBr, cm<sup>-1</sup>) 3302, 2973, 2926, 2556, 1728, 1709, 1647, 1525, 1242

- (2S)-6-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]hexanoic acid (Compound No. 3-11)
- 10 • (2R)-2-(2, 2-Dimethyl-3-mercaptopropionylamino)-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 3-12)
- (2R)-3-[4-(N-Ethyl-N-methylamino)benzylthio]-2-(2, 2-dimethyl-3-mercaptopropionylamino)propionic acid (Compound No. 3-13)
- (2R)-2-(2, 2-Dimethyl-3-mercaptopropionylamino)-3-[4-(N-isopropyl-N-methylamino)benzylthio]propionic acid (Compound No. 3-14)
- 15 • (2R)-3-[4-(N-tert-Butyl-N-methylamino)benzylthio]-2-(2, 2-dimethyl-3-mercaptopropionylamino)propionic acid (Compound No. 3-15)
- (2R)-3-[4-(N, N-Diethylamino)benzylthio]-2-(2, 2-dimethyl-3-mercaptopropionylamino)propionic acid (Compound No. 3-16)
- 20 • (2S)-2-(2, 2-Dimethyl-3-mercaptopropionylamino)-4-[4-(N, N-dimethylamino)benzylthio]butyric acid (Compound No. 3-17)
- (2S)-2-(2, 2-Dimethyl-3-mercaptopropionylamino)-6-[4-(N, N-dimethylamino)benzylthio]hexanoic acid (Compound No. 3-18)
- 25 • (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-2-mercaptopropionylamino]propionic acid (Compound No. 3-19)

Diastereo isomer of compound No. 3-20

$[\alpha]_D^{20}$  -53.9° (c=0.16, methanol)  
 30 IR (Film, cm<sup>-1</sup>) 3306, 2926, 2550, 1728, 1659, 1612, 1521

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2R)-2-mercaptopropionylamino]propionic acid (Compound No. 3-20)

35 Diastereo isomer of compound No. 3-19

$[\alpha]_D^{20}$  -36.5° (c=0.26, methanol)  
 IR (Film, cm<sup>-1</sup>) 3306, 2926, 2552, 1729, 1659, 1612, 1521

- 40 • (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2R)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-21)

Diastereo isomer of compound No. 3-1 and enantiomer of compound No. 3-2

45 mp 91.5-92.5°C  
 $[\alpha]_D^{20}$  -43.2° (c=0.31, methanol)  
 IR (KBr, cm<sup>-1</sup>) 3368, 2976, 2930, 2557, 1708, 1651, 1515, 1455, 1346

- 50 • (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2RS)-2-ethyl-3-mercaptopropionylamino]propionic acid (Compound No. 3-22)

IR (Film, cm<sup>-1</sup>) 3305, 2963, 2930, 1731, 1656, 1612, 1522, 1350, 1216, 755

- 55 • (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2RS)-3-mercapto-2-propylpropionylamino]propionic acid (Compound No. 3-23)

IR (Film, cm<sup>-1</sup>) 3305, 2957, 2930, 2557, 1729, 1651, 1612, 1521

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2RS)-2-isopropyl-3-mercaptopropionylamino]propionic acid (Compound No. 3-24)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2555, 1730, 1653, 1521, 1350, 1217

- (2R)-2-[(2RS)-2-Benzyl-3-mercaptopropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid (Compound No. 3-25)

IR (Film,  $\text{cm}^{-1}$ ) 3305, 2922, 1729, 1651, 1612, 1521, 1350, 1218, 821, 753, 701

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S or 2R)-2-phenetyl-3-mercaptopropionylamino]propionic acid (Compound No. 3-26)

Diastereo isomer of compound No. 3-27

$[\alpha]_D^{20}$  -34.2° (c=0.87, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2926, 1731, 1652, 1612, 1521, 1454, 1350, 1217, 753, 700

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2R or 2S)-2-phenetyl-3-mercaptopropionylamino]propionic acid (Compound No. 3-27)

Diastereo isomer of compound No. 3-26

$[\alpha]_D^{20}$  -53.4° (c=0.74, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2925, 1730, 1651, 1612, 1521, 1454, 1350, 1218, 753, 700

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(3RS)-3-mercaptopbutyrylamino]propionic acid (Compound No. 3-28)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2922, 2554, 1651, 1522, 1446, 1351

- (2R)-3-[3-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-29)

$[\alpha]_D^{20}$  -70.8° (c=0.46, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2972, 2557, 1729, 1658, 1603, 1439, 851

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-(4-mercaptopbutyrylamino)propionic acid (Compound No. 3-30)

$[\alpha]_D^{20}$  -45.4° (c=0.48, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2923, 1723, 1612, 1522, 1414, 1350, 1224, 946, 822

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S or 2R)-4-mercapto-2-methylbutyrylamino]propionic acid (Compound No. 3-31)

Diastereo isomer of compound No. 3-32

$[\alpha]_D^{20}$  -33.9° (c=0.32, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3305, 2931, 1731, 1650, 1612, 1521, 1349, 1215, 946, 821, 754

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2R or 2S)-4-mercapto-2-methylbutyrylamino]propionic acid (Compound No. 3-32)


Diastereo isomer of compound No. 3-31

$[\alpha]_D^{20}$  -68.1° (c=0.93, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2932, 1730, 1612, 1521, 1217, 947, 821, 755

## Example 4

(2RS)-3-[4-(N, N-Dimethylamino)benzyloxy]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No.4-1)



A 28% aqueous ammonia solution (2 ml) is added to (2S)-2-[(2S)-3-benzoylthio-2-methylpropionylamino]-3-[4-(N, N-dimethylamino)benzyloxy]propionic acid (Compound No. 2-33, 85 mg) and the mixture is stirred at room temperature for 20 minutes. The reaction mixture is concentrated under reduced pressure to remove ammonia and the obtained aqueous solution is washed with diethyl ether. Next the reaction mixture is acidified with acetic acid and the whole is extracted with ethyl acetate. The organic layer is washed with a saturated sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained oily residue is purified by silica gel column chromatography to give 11 mg (16.9%) of the titled compound.


IR (Film,  $\text{cm}^{-1}$ ) 3317, 2930, 2360, 1730, 1523, 1102, 811

The following compounds are obtained by a method similar to Example 4.

- (2RS)-3-[4-(N, N-Dimethylamino)benzyloxy]-2-mercaptoacetylaminopropionic acid (Compound No. 4-2)
- (2RS)-3-[4-(N, N-Dimethylamino)benzyloxy]-2-(3-mercaptopropionylamino)propionic acid (Compound No. 4-3)
- (2RS)-3-[4-(N, N-Dimethylamino)benzyloxy]-2-(6-mercaptohexanoylamino)propionic acid (Compound No. 4-4)
- (2RS)-3-[4-(N-Ethyl-N-methylamino)benzyloxy]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 4-5)
- (2RS)-3-[4-(N, N-Diethylamino)benzyloxy]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 4-6)
- (2RS)-4-[4-(N, N-Dimethylamino)benzyloxy]-2-[(2S)-3-mercapto-2-methylpropionylamino]butyric acid (Compound No. 4-7)
- (2RS)-6-[4-(N, N-Dimethylamino)benzyloxy]-2-[(2S)-3-mercapto-2-methylpropionylamino]hexanoic acid (Compound No. 4-8)
- (2RS)-2-(2, 2-Dimethyl-3-mercaptopropionylamino)-3-[4-(N, N-dimethylamino)benzyloxy]propionic acid (Compound No. 4-9)
- (2RS)-3-[4-(N-Ethyl-N-methylamino)benzyloxy]-2-(2, 2-dimethyl-3-mercaptopropionylamino)propionic acid (Compound No. 4-10)
- (2RS)-3-[4-(N, N-Diethylamino)benzyloxy]-2-(2, 2-dimethyl-3-mercaptopropionylamino)propionic acid (Compound No. 4-11)
- (2RS)-2-(2, 2-Dimethyl-3-mercaptopropionylamino)-4-[4-(N, N-dimethylamino)benzyloxy]butyric acid (Compound No. 4-12)
- (2RS)-2-(2, 2-Dimethyl-3-mercaptopropionylamino)-6-[4-(N, N-dimethylamino)benzyloxy]hexanoic acid (Compound No. 4-13)
- (2RS)-3-[3-(N, N-Dimethylamino)benzyloxy]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 4-14)

## Example 5

(2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid methylamide (Compound No. 5-1)



To (2R)-2-tert-butoxycarbonylamino-3-[4-(N, N-dimethylamino)benzylthio]propionic acid methylamide (Reference compound No. 6-1, 200 mg) is added 4 N hydrochloric acid/dioxane (1.5 ml) and the mixture is stirred at room temperature for one hour. The reaction mixture is concentrated under reduced pressure and the obtained oily residue is dissolved in methylene chloride (5 ml). To the solution are added N-methylmorpholin (0.119 ml), 1-hydroxybenzotriazole (109 mg), (2S)-3-benzoylthio-2-methylpropionic acid (182 mg), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (135 mg) and N-methylmorpholin (0.077 ml) successively under ice-cooling, and the mixture is stirred at room temperature overnight. To the reaction mixture is added a 5% aqueous sodium hydrogencarbonate solution and the whole is extracted with ethyl acetate. The organic layer is washed with a 5% aqueous sodium hydrogencarbonate solution and a saturated sodium chloride solution successively, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained oily residue is purified by silica gel column chromatography to give 170 mg (66.4%) of the titled compound.

mp 137.0-155.0°C

$[\alpha]_D^{20}$  -99.7° (c=0.49, methanol)


IR (KBr,  $\text{cm}^{-1}$ ) 3281, 3066, 1640, 1521, 1410

The following compound is obtained by a method similar to Example 5.

- (2R)-2-[(2S)-3-Benzoylthio-2-methylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio]propionic acid benzylamide (Compound No. 5-2)

#### Example 6

(2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid methylamide (Compound No. 6-1)



To a solution of (2R)-2-[(2S)-3-benzoylthio-2-methylpropionylamino]-3-[4-(N, N-dimethylamino)benzylthio] propionic acid methylamide (Compound No. 5-1, 50 mg) in methanol (2 ml) is added 1 N sodium hydroxide (0.13 ml) and the mixture is stirred at room temperature for 15 minutes. The reaction mixture is adjusted to pH 7 by adding a 5% aqueous citric acid solution and concentrated under reduced pressure. Water is added to the obtained oily residue and the whole is extracted with ethyl acetate. The organic layer is washed with a saturated sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give 18 mg (46.2%) of the titled compound.

mp 133.0-137.0°C

$[\alpha]_D^{20}$  -43.8° (c=0.20, chloroform)


IR (KBr,  $\text{cm}^{-1}$ ) 3292, 2556, 1639, 1524, 1355

The following compound is obtained by a method similar to Example 6.

- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid benzylamide (Compound No. 6-2)

#### Example 7

(2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-2-methyl-3-methylthiopropionylamino]propionic acid (Compound No. 7-1)



To a solution of (2R)-3-[4-(N, N-dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-1, 300 mg) in ethanol (6.4 ml) is added 2 N sodium hydroxide (0.84 ml) under ice-cooling. To the mixture is added a solution of methyl iodide (0.052 ml) in ethanol (2 ml) dropwise and the obtained mixture is stirred for 25 minutes. The reaction mixture is adjusted to pH 4 by adding a 5% aqueous citric acid solution and the whole is extracted with ethyl acetate. The organic layer is washed with a 5% aqueous citric acid solution and a saturated sodium chloride solution successively, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The obtained oily residue is purified by silica gel column chromatography to give 143 mg (50.3%) of the titled compound.

$[\alpha]_{\text{D}}^{20} -76.1^\circ$  (c=0.31, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3306, 2970, 1890, 1731, 1650, 1522, 1424, 1130, 668

The following compound is obtained by a method similar to Example 7.


- (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-benzylthio-2-methylpropionylamino]propionic acid (Compound No. 7-2)

$[\alpha]_{\text{D}}^{20} -49.1^\circ$  (c=0.51, methanol)

IR (Film,  $\text{cm}^{-1}$ ) 3307, 2917, 1730, 1657, 1612, 1521, 1453, 1351, 1217, 755, 703

#### Example 8

Ethyl (2R)-3-[4-(N, N-dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionate (Compound No. 8-1)



Anhydrous sodium sulfate (3 g) is added to a solution of (2R)-3-[4-(N, N-dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid (Compound No. 3-1, 300 mg) and p-toluenesulfonic acid monohydrate (240 mg) in ethanol (10 ml), and the mixture is refluxed for 3.5 hours. Sodium sulfate is removed by filtration and the

filtrate is concentrated under reduced pressure. To the obtained oily residue is added a 5% aqueous sodium hydrogen-carbonate solution and the whole is extracted with ethyl acetate. The organic layer is washed with a 5% aqueous sodium hydrogencarbonate solution, a 5% aqueous citric acid solution and a saturated sodium chloride solution successively, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 211 mg (65.3%) of the titled compound.

mp 60.5-64.0°C

$[\alpha]_D^{20}$  -84.5° (c=0.48, methanol)

IR (KBr, cm<sup>-1</sup>) 3295, 2974, 2574, 1722, 1648, 1524, 1446, 1058, 811

The following compounds are obtained by a method similar to Example 8.

- Benzyl (2R)-3-[4-(N, N-dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionate (Compound No. 8-2)
- Ethyl (2R)-2-(2, 2-dimethyl-3-mercaptopropionylamino)-3-[4-(N, N-dimethylamino)benzylthio]propionate (Compound No. 8-3)
- Benzyl (2R)-2-(2, 2-dimethyl-3-mercaptopropionylamino)-3-[4-(N, N-dimethylamino)benzylthio]propionate (Compound No. 8-4)

## Formulation

General formulation examples of oral preparations and injections using the present compounds are shown below.

### 1) Tablet

| Formulation 1 in 100 mg        |         |
|--------------------------------|---------|
| present compound               | 1 mg    |
| lactose                        | 66.4 mg |
| cornstarch                     | 20 mg   |
| calcium carboxymethylcellulose | 6 mg    |
| hydroxypropylcellulose         | 4 mg    |
| magnesium stearate             | 0.6 mg  |

Tablets according to the prescription as above are coated with 2 mg/tablet of a coating agent (this is a conventional coating agent such as hydroxypropylmethylcellulose, macrogol or silicone resin) to obtain desired coated tablets. (The same is applied to tablets mentioned below.)

| Formulation 2 in 100 mg        |         |
|--------------------------------|---------|
| present compound               | 5 mg    |
| lactose                        | 62.4 mg |
| cornstarch                     | 20 mg   |
| calcium carboxymethylcellulose | 6 mg    |
| magnesium stearate             | 0.6 mg  |
| hydroxypropylcellulose         | 4 mg    |
| coating agent                  | 2 mg    |

5

10

15

20

25

30

35

40

45

50

55

| Formulation 3 in 100 mg        |       |
|--------------------------------|-------|
| present compound               | 20 mg |
| lactose                        | 51 mg |
| cornstarch                     | 15 mg |
| calcium carboxymethylcellulose | 5 mg  |
| hydroxypropylcellulose         | 5 mg  |
| magnesium stearate             | 1 mg  |
| talc                           | 1 mg  |
| coating agent                  | 2 mg  |

| Formulation 4 in 100 mg        |       |
|--------------------------------|-------|
| present compound               | 40 mg |
| lactose                        | 34 mg |
| cornstarch                     | 10 mg |
| calcium carboxymethylcellulose | 5 mg  |
| hydroxypropylcellulose         | 5 mg  |
| magnesium stearate             | 2 mg  |
| talc                           | 2 mg  |
| coating agent                  | 2 mg  |

| Formulation 5 in 220 mg        |        |
|--------------------------------|--------|
| present compound               | 100 mg |
| lactose                        | 67 mg  |
| cornstarch                     | 20 mg  |
| calcium carboxymethylcellulose | 10 mg  |
| hydroxypropylcellulose         | 10 mg  |
| magnesium stearate             | 4 mg   |
| talc                           | 4 mg   |
| coating agent                  | 5 mg   |

## 2) Capsule

| Formulation 1 in 150 mg |        |
|-------------------------|--------|
| present compound        | 5 mg   |
| lactose                 | 145 mg |

Varying the mixing ratio of the present compound to lactose, capsules having the contents of the present compound of 10 mg/capsule, 30 mg/capsule, 50 mg/capsule and 100 mg/capsule are also prepared.

## 3) Granule

| Formulation 1 in 100 mg    |         |
|----------------------------|---------|
| present compound           | 30 mg   |
| mannitol                   | 46.5 mg |
| polyvinyl pyrrolidone K-30 | 7 mg    |
| eudragit RL                | 15 mg   |
| triacetin                  | 1.5 mg  |

| Formulation 2 in 130 mg |       |
|-------------------------|-------|
| present compound        | 50 mg |
| lactose                 | 55 mg |
| white potato starch     | 20 mg |
| hydroxypropylcellulose  | 4 mg  |
| talc                    | trace |

## 4) Injection

| Formulation 1 in 10 ml |           |
|------------------------|-----------|
| present compound       | 10-100 mg |
| sodium chloride        | 90 mg     |
| sodium hydroxide       | q.s.      |
| sterile purified water | q.s.      |

## Pharmacological Test

Izumi et al. had reported a method of measuring  $LTA_4$  hydrolase activity by measuring an amount of  $LTB_4$  produced by an enzymatic reaction using  $LTA_4$  as a substrate (Biochem. Biophys. Res. Commun., 135, 139-145 (1986)). Effects of the present compounds on  $LTA_4$  hydrolase were examined according to the method described in the literature.

## Experimental Method

An enzyme preparation used in this pharmacological test was prepared by extracting roughly from guinea pig lung by the following method, according to the method of Izumi et al. (Biochem. Biophys. Res. Commun., 135, 139-145 (1986)) and the method of Evans et al. (Biochem. Biophys. Acta, 840, 43-50 (1985)).

Lungs were excised from Hartley guinea pigs (body weight: 330 g). The lungs were homogenized in phosphoric acid buffer (50 mM, pH 7.4, containing 1 mM ethylenediaminetetraacetic acid (EDTA) and 1 mM dithiothreitol (DTT)) having weight three times that of the lungs under ice-cooling. The homogenate was centrifuged at low speed ( $800 \times g$ ) for 20 minutes, centrifuged at high speed ( $10,000 \times g$ ) for 20 minutes and ultracentrifuged ( $100,000 \times g$ ) for 60 minutes to give a supernatant. The supernatant was brought to 40% saturation by adding a saturated aqueous ammonium sulfate solution (pH 7.0-7.2, containing 1 mM DTT) dropwise under ice-cooling and centrifuged at high speed ( $10,000 \times g$ ) for 20 minutes. The resulting supernatant was brought to 70% saturation by adding a saturated aqueous ammonium sulfate solution (pH 7.0-7.2, containing 1 mM DTT) dropwise and centrifuged at high speed ( $10,000 \times g$ ) for 20 minutes. The obtained pellet was dissolved in 2 ml of Tris-acetic acid buffer (20 mM, pH 7.8, containing 1 mM DTT) and dialyzed in 2 liters of the solution to give the enzyme preparation.

LTA<sub>4</sub> used, which is the substrate, was prepared by hydrolyzing LTA<sub>4</sub> methyl ester and dissolved in ethanol.

In order to examine effects of the present compounds on the enzyme preparation, reactions were performed under the following condition using mixed solutions consisting of the composition shown in Table 1.

Table 1

|                      |                         |
|----------------------|-------------------------|
| HEPES buffer         | 50 mM, pH 7.8           |
| Enzyme preparation   | 0.4-0.6 mg protein      |
| LTA <sub>4</sub>     | 63 $\mu$ M              |
| Aqueous DTT solution | 3 mM                    |
| Test compound        | $10^{-8}$ - $10^{-3}$ M |

The above-mentioned solution (50  $\mu$ l) was incubated at 37°C for one minute. To the reaction mixture was added 100  $\mu$ l of a mixed liquid of acetonitrile-ethanol-acetic acid (150:50:3, volume ratio) under ice-cooling. The mixture was allowed to stand at -20°C for 30 minutes and centrifuged at high speed ( $10,000 \times g$ ) for five minutes to give a supernatant. An amount of LTB<sub>4</sub> produced in the supernatant was measured by high-speed liquid chromatography.

The degree of the inhibitory effect of each test compound on LTA<sub>4</sub> hydrolase is expressed by the inhibition rate calculated by the following equation.

$$\text{Inhibition rate (\%)} = \frac{A-B}{A} \times 100$$

A: amount of LTB<sub>4</sub> formed in the absence of the test compound

B: amount of LTB<sub>4</sub> formed in the presence of the test compound

## Results

As examples of the experimental results, Table 2 shows concentrations of compound Nos. 3-1, 3-3, 3-9, 3-19, 3-21, 3-22, 3-23, 3-24, 3-26, 3-27, 3-28 and 8-1 required to inhibit LTA<sub>4</sub> hydrolase by 50%, i.e., IC<sub>50</sub>.

Table 2

|                  | IC <sub>50</sub> (M) |
|------------------|----------------------|
| Compound No. 3-1 | $2.4 \times 10^{-7}$ |
| Compound No. 3-3 | $4.7 \times 10^{-7}$ |
| Compound No. 3-9 | $9.0 \times 10^{-7}$ |

Table 2 (continued)


|                   | IC <sub>50</sub> (M) |
|-------------------|----------------------|
| Compound No. 3-19 | 5.6×10 <sup>-6</sup> |
| Compound No. 3-21 | 1.5×10 <sup>-6</sup> |
| Compound No. 3-22 | 4.0×10 <sup>-7</sup> |
| Compound No. 3-23 | 2.9×10 <sup>-7</sup> |
| Compound No. 3-24 | 1.1×10 <sup>-6</sup> |
| Compound No. 3-26 | 5.0×10 <sup>-7</sup> |
| Compound No. 3-27 | 3.8×10 <sup>-6</sup> |
| Compound No. 3-28 | 7.4×10 <sup>-6</sup> |
| Compound No. 8-1  | 5.9×10 <sup>-7</sup> |

As shown in Table 2, the present compounds were found to inhibit the LTA<sub>4</sub> hydrolase activity remarkably at the low concentrations.

Since the above-mentioned pharmacological test shows that the present compounds have the excellent inhibitory effects on LTA<sub>4</sub> hydrolase, the compounds are expected to be excellent medicines, in particular, therapeutic agents for inflammatory diseases such as rheumatic diseases, psoriasis, inflammatory intestinal diseases, gout and cystic fibrosis, in which LTB<sub>4</sub> is concerned.

#### INDUSTRIAL APPLICABILITY

The present invention provides novel amino acid derivatives containing sulfur or oxygen and having an N, N-dialkylaminophenyl group at their side chain which have inhibitory effects on LTA<sub>4</sub> hydrolase and are useful as medicines, in particular, therapeutic agents for inflammatory diseases such as rheumatic diseases, psoriasis, inflammatory intestinal diseases, gout and cystic fibrosis, in which LTB<sub>4</sub> is concerned.




















|           | Compound      | (a) | -R <sup>2</sup> | (b) | -R <sup>3</sup> | -R <sup>4</sup>  | Z | -A <sup>2</sup> -                  | -A <sup>3</sup> -  |
|-----------|---------------|-----|-----------------|-----|-----------------|------------------|---|------------------------------------|--------------------|
| Reference | 1 - ① [3 - ①] | R   | -COOH           | p   | -Me             | -Me              | S | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|           | 1 - 2 [3 - 2] | R   | -COOH           | p   | -Me             | -Et              | S | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|           | 1 - 3 [3 - 3] | R   | -COOH           | p   | -Me             | -Pr <sup>i</sup> | S | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|           | 1 - 4 [3 - 4] | R   | -COOH           | p   | -Me             | -Bu <sup>i</sup> | S | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|           | 1 - ⑤ [3 - 5] | R   | -COOH           | p   | -Et             | -Et              | S | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|           | 1 - ⑥ [3 - ⑥] | S   | -COOH           | p   | -Me             | -Me              | S | -(CH <sub>2</sub> ) <sub>2</sub> - | -CH <sub>2</sub> - |
|           | 1 - 7 [3 - 7] | S   | -COOH           | p   | -Me             | -Me              | S | -(CH <sub>2</sub> ) <sub>4</sub> - | -CH <sub>2</sub> - |
|           | 1 - ⑧ [3 - ③] | R   | -COOH           | m   | -Me             | -Me              | S | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|           | 1 - ⑨ [3 - ⑭] | S   | -COOH           | p   | -Me             | -Me              | S | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |

(continued)


|    | Compound  |                | (a) | -R <sup>2</sup> | (b) | -R <sup>3</sup> | -R <sup>4</sup> | Z | -A <sup>2</sup> -                  | -A <sup>3</sup> -  |
|----|-----------|----------------|-----|-----------------|-----|-----------------|-----------------|---|------------------------------------|--------------------|
| 5  | Reference | 2 - ① [3 - 8]  | S   | -COOH           | p   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|    |           | 2 - 2 [3 - 9]  | S   | -COOH           | p   | -Me             | -Et             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|    |           | 2 - 3 [3 - 10] | S   | -COOH           | p   | -Et             | -Et             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|    |           | 2 - 4 [3 - 11] | S   | -COOH           | p   | -Me             | -Me             | O | -(CH <sub>2</sub> ) <sub>2</sub> - | -CH <sub>2</sub> - |
|    |           | 2 - 5 [3 - 12] | S   | -COOH           | p   | -Me             | -Me             | O | -(CH <sub>2</sub> ) <sub>4</sub> - | -CH <sub>2</sub> - |
|    |           | 2 - 6          | S   | -COOH           | m   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|    |           | 2 - 7          | R   | -COOH           | p   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|    |           | [3 - 15]       | R   | -COOH           | m   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 15 |           | [3 - 16]       | S   | -COOH           | p   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|    | Reference | 6 - ①          | R   | -CONHMe         | p   | -Me             | -Me             | S | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
|    |           | 6 - 2          | R   | -CONHBzl        | p   | -Me             | -Me             | S | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |




| Compound          | $R^1-S-A^1$   | $-R^c$   |
|-------------------|---|--|
| Reference 4 - (1) | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad\quad\quad\text{Me}$                 | -COCl  |
| Reference 5 - (1) | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad\quad\quad\text{Me}$                 | -COO-  -NO <sub>2</sub>   |
| 5 - (2)           | $\text{PhCO-S-CH}_2\text{-}$  | -COO-  -NO <sub>2</sub>   |
| 5 - (3)           | $\text{PhCO-S-(CH}_2)_2\text{-}$  | -COO-  -NO <sub>2</sub>   |
| 5 - 4             | $\text{PhCO-S-(CH}_2)_5\text{-}$  | -COO-  -NO <sub>2</sub>   |
| 5 - 5             | $\text{PhCO-S-CH}_2\text{-CMe}_2\text{-}$                                     | -COO-  -NO <sub>2</sub>   |
| 5 - (6)           | $\text{PhCO-S-CH-}$<br>$\quad\quad\quad\text{Me}$                             | -COO-  -NO <sub>2</sub>   |
| 5 - (7)           | $\text{PhCO-S-CH-}$<br>$\quad\quad\quad\text{Me}$                             | -COO-  -NO <sub>2</sub>   |
| 5 - (8)           | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad\quad\quad\text{Me}$                 | -COO-  -NO <sub>2</sub>   |
| 5 - (9)           | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad\quad\quad\text{Et}$                 | -COO-  -NO <sub>2</sub>   |
| 5 - (10)          | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad\quad\quad\text{Pr}$                 | -COO-  -NO <sub>2</sub>  |
| 5 - (11)          | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad\quad\quad\text{Pr}^i$               | -COO-  -NO <sub>2</sub> |
| 5 - (12)          | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad\quad\quad\text{CH}_2\text{-Ph}$     | -COO-  -NO <sub>2</sub> |
| 5 - (13)          | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad\quad\quad\text{(CH}_2)_2\text{-Ph}$ | -COO-  -NO <sub>2</sub> |
| 5 - (14)          | $\text{PhCO-S-CH-CH}_2\text{-}$<br>$\quad\quad\quad\text{Me}$                 | -COO-  -NO <sub>2</sub> |
| 5 - (15)          | $\text{PhCO-S-(CH}_2)_3\text{-}$  | -COO-  -NO <sub>2</sub> |
| 5 - (16)          | $\text{PhCO-S-(CH}_2)_2\text{-CH-}$<br>$\quad\quad\quad\text{Me}$             | -COO-  -NO <sub>2</sub> |




| Compound                                    | R <sup>1</sup> -S-A <sup>1</sup>         | (a) | -R <sup>2</sup> | (b) | -R <sup>3</sup> | -R <sup>4</sup>  | Z | -A <sup>2</sup>                  | -A <sup>3</sup>  |
|---|--|-----|-----------------|-----|-----------------|------------------|---|----------------------------------|------------------|
| 1 - $\begin{pmatrix} 1 \\ 2 \end{pmatrix}$  | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me   | R   | -COOH           | P   | -Me             | -Me              | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - $\begin{pmatrix} 2 \\ 4 \end{pmatrix}$  | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me   | S   | -COOH           | P   | -Me             | -Me              | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - $\begin{pmatrix} 2 \\ 3 \end{pmatrix}$  | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me   | R   | -COOH           | P   | -Me             | -Me              | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - 4                                       | PhCO-S-(CH <sub>2</sub> ) <sub>5</sub>   | R   | -COOH           | P   | -Me             | -Me              | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - 5                                       | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me   | R   | -COOH           | P   | -Me             | -Et              | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - 6                                       | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me   | R   | -COOH           | P   | -Me             | -Pr <sup>i</sup> | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - 7                                       | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me   | R   | -COOH           | P   | -Me             | -Bu <sup>t</sup> | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - $\begin{pmatrix} 8 \\ 9 \end{pmatrix}$  | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me   | R   | -COOH           | P   | -Et             | -Et              | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - $\begin{pmatrix} 9 \\ 10 \end{pmatrix}$ | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me   | S   | -COOH           | P   | -Me             | -Me              | S | -(CH <sub>2</sub> ) <sub>2</sub> | -CH <sub>2</sub> |
| 2 - 10                                      | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me   | S   | -COOH           | P   | -Me             | -Me              | S | -(CH <sub>2</sub> ) <sub>4</sub> | -CH <sub>2</sub> |
| 2 - 11                                      | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> | R   | -COOH           | P   | -Me             | -Me              | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - 12                                      | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> | R   | -COOH           | P   | -Me             | -Et              | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - 13                                      | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> | R   | -COOH           | P   | -Me             | -Pr <sup>i</sup> | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - 14                                      | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> | R   | -COOH           | P   | -Me             | -Bu <sup>t</sup> | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - 15                                      | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> | R   | -COOH           | P   | -Et             | -Et              | S | -CH <sub>2</sub>                 | -CH <sub>2</sub> |
| 2 - 16                                      | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> | S   | -COOH           | P   | -Me             | -Me              | S | -(CH <sub>2</sub> ) <sub>2</sub> | -CH <sub>2</sub> |
| 2 - 17                                      | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> | S   | -COOH           | P   | -Me             | -Me              | S | -(CH <sub>2</sub> ) <sub>4</sub> | -CH <sub>2</sub> |




| Compound | R <sup>1</sup> -S-A <sup>1</sup> -         | (a) | -R <sup>2</sup> | (b) | -R <sup>3</sup> | -R <sup>4</sup> | Z | -A <sup>2</sup> -                  | -A <sup>3</sup> -  |
|----------|--|-----|-----------------|-----|-----------------|-----------------|---|------------------------------------|--------------------|
| 2-18     | PhCO-S-CH <sub>2</sub> -                   | s   | -COOH           | p   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 2-19     | PhCO-S-(CH <sub>2</sub> ) <sub>2</sub> -   | s   | -COOH           | p   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 2-20     | PhCO-S-(CH <sub>2</sub> ) <sub>5</sub> -   | s   | -COOH           | p   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 2-21     | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me     | s   | -COOH           | p   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 2-22     | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me     | s   | -COOH           | p   | -Me             | -Et             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 2-23     | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me     | s   | -COOH           | p   | -Et             | -Et             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 2-24     | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me     | s   | -COOH           | p   | -Me             | -Me             | O | -(CH <sub>2</sub> ) <sub>2</sub> - | -CH <sub>2</sub> - |
| 2-25     | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me     | s   | -COOH           | p   | -Me             | -Me             | O | -(CH <sub>2</sub> ) <sub>4</sub> - | -CH <sub>2</sub> - |
| 2-26     | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> - | s   | -COOH           | p   | -Me             | -Me             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 2-27     | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> - | s   | -COOH           | p   | -Me             | -Et             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 2-28     | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> - | s   | -COOH           | p   | -Et             | -Et             | O | -CH <sub>2</sub> -                 | -CH <sub>2</sub> - |
| 2-29     | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> - | s   | -COOH           | p   | -Me             | -Me             | O | -(CH <sub>2</sub> ) <sub>2</sub> - | -CH <sub>2</sub> - |
| 2-30     | PhCO-S-CH <sub>2</sub> -CMe <sub>2</sub> - | s   | -COOH           | p   | -Me             | -Me             | O | -(CH <sub>2</sub> ) <sub>4</sub> - | -CH <sub>2</sub> - |




| Compound | $R^1-S-A^1-$  | (a) | $-R^2$ | (b) | $-R^3$ | $-R^4$ | Z | $-A^2-$         | $-A^3-$         |
|----------|---|-----|--------|-----|--------|--------|---|-----------------|-----------------|
| 2-(3 1)  | $\text{PhCO-S-CH-}$<br>$\quad \quad \quad \text{Me}$                            | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(3 2)  | $\text{PhCO-S-CH-}$<br>$\quad \quad \quad \text{Me}$                            | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(3 3)  | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad \quad \quad \text{Me}$                | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(3 4)  | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad \quad \quad \text{Et}$                | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(3 5)  | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad \quad \quad \text{Pr}$                | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(3 6)  | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad \quad \quad \text{Pr}$                | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(3 7)  | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad \quad \quad \text{CH}_2\text{Ph}$     | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(3 8)  | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad \quad \quad (\text{CH}_2)_2\text{Ph}$ | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(3 9)  | $\text{PhCO-S-CH-CH}_2-$<br>$\quad \quad \quad \text{Me}$                       | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(1 0)  | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad \quad \quad \text{Me}$                | R   | -COOH  | m   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(4 1)  | $\text{PhCO-S-(CH}_2)_3-$   | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(4 2)  | $\text{PhCO-S-(CH}_2)_2\text{-CH-}$<br>$\quad \quad \quad \text{Me}$            | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-(4 3)  | $\text{PhCO-S-(CH}_2)_2\text{-CH-}$<br>$\quad \quad \quad \text{Me}$            | R   | -COOH  | p   | -Me    | -Me    | S | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-4 5    | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad \quad \quad \text{Me}$                | S   | -COOH  | m   | -Me    | -Me    | O | $-\text{CH}_2-$ | $-\text{CH}_2-$ |
| 2-4 6    | $\text{PhCO-S-CH}_2\text{-CH-}$<br>$\quad \quad \quad \text{Me}$                | R   | -COOH  | p   | -Me    | -Me    | O | $-\text{CH}_2-$ | $-\text{CH}_2-$ |




| Compound | $R^1-S-A^1-$ | (a)   | $-R^2$ | (b)   | $-R^3$ | $-R^4$ | Z                | $-A^2-$ | $-A^3-$      |          |
|----------|--------------|---|--------|-------|--------|--------|------------------|---------|--------------|----------|
| 5        | 3 - (1)      | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$ | R      | -COOH | p      | -Me    | -Me              | S       | $-CH_2-$     | $-CH_2-$ |
|          | 3 - (2)      | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$ | S      | -COOH | p      | -Me    | -Me              | S       | $-CH_2-$     | $-CH_2-$ |
| 10       | 3 - (3)      | $H-S-CH_2-$                                       | R      | -COOH | p      | -Me    | -Me              | S       | $-CH_2-$     | $-CH_2-$ |
|          | 3 - (4)      | $H-S-(CH_2)_2-$                                   | R      | -COOH | p      | -Me    | -Me              | S       | $-CH_2-$     | $-CH_2-$ |
|          | 3 - 5        | $H-S-(CH_2)_5-$                                   | R      | -COOH | p      | -Me    | -Me              | S       | $-CH_2-$     | $-CH_2-$ |
| 15       | 3 - 6        | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$ | R      | -COOH | p      | -Me    | -Et              | S       | $-CH_2-$     | $-CH_2-$ |
|          | 3 - 7        | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$ | R      | -COOH | p      | -Me    | -Pr <sup>i</sup> | S       | $-CH_2-$     | $-CH_2-$ |
| 20       | 3 - 8        | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$ | R      | -COOH | p      | -Me    | -Bu <sup>i</sup> | S       | $-CH_2-$     | $-CH_2-$ |
|          | 3 - (9)      | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$ | R      | -COOH | p      | -Et    | -Et              | S       | $-CH_2-$     | $-CH_2-$ |
| 25       | 3 - (10)     | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$ | S      | -COOH | p      | -Me    | -Me              | S       | $-(CH_2)_2-$ | $-CH_2-$ |
|          | 3 - 11       | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$ | S      | -COOH | p      | -Me    | -Me              | S       | $-(CH_2)_4-$ | $-CH_2-$ |
| 30       | 3 - 12       | $H-S-CH_2-CMe_2$                                  | R      | -COOH | p      | -Me    | -Me              | S       | $-CH_2-$     | $-CH_2-$ |
|          | 3 - 13       | $H-S-CH_2-CMe_2$                                  | R      | -COOH | p      | -Me    | -Et              | S       | $-CH_2-$     | $-CH_2-$ |
|          | 3 - 14       | $H-S-CH_2-CMe_2$                                  | R      | -COOH | p      | -Me    | -Pr <sup>i</sup> | S       | $-CH_2-$     | $-CH_2-$ |
| 35       | 3 - 15       | $H-S-CH_2-CMe_2$                                  | R      | -COOH | p      | -Me    | -Bu <sup>i</sup> | S       | $-CH_2-$     | $-CH_2-$ |
|          | 3 - 16       | $H-S-CH_2-CMe_2$                                  | R      | -COOH | p      | -Et    | -Et              | S       | $-CH_2-$     | $-CH_2-$ |
|          | 3 - 17       | $H-S-CH_2-CMe_2$                                  | S      | -COOH | p      | -Me    | -Me              | S       | $-(CH_2)_2-$ | $-CH_2-$ |
| 40       | 3 - 18       | $H-S-CH_2-CMe_2$                                  | S      | -COOH | p      | -Me    | -Me              | S       | $-(CH_2)_4-$ | $-CH_2-$ |



| Compound | $R^1-S-A^1$ | (a)   | $-R^2$ | (b)   | $-R^3$ | $-R^4$ | Z   | $-A^2$ | $-A^3$   |          |
|----------|-------------|---|--------|-------|--------|--------|-----|--------|----------|----------|
| 5        | 3-(19)      | $H-S-\underset{\text{Me}}{\underset{ }{CH}}$        | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
|          | 3-(20)      | $H-S-\underset{\text{Me}}{\underset{ }{CH}}$        | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
| 10       | 3-(21)      | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$   | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
|          | 3-(22)      | $H-S-CH_2-\underset{Et}{\underset{ }{CH}}$          | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
| 15       | 3-(23)      | $H-S-CH_2-\underset{Pr}{\underset{ }{CH}}$          | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
|          | 3-(24)      | $H-S-CH_2-\underset{Pr}{\underset{ }{CH}}$          | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
| 20       | 3-(25)      | $H-S-CH_2-\underset{CH_2-Ph}{\underset{ }{CH}}$     | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
|          | 3-(26)      | $H-S-CH_2-\underset{(CH_2)_2-Ph}{\underset{ }{CH}}$ | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
| 25       | 3-(27)      | $H-S-CH_2-\underset{(CH_2)_2-Ph}{\underset{ }{CH}}$ | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
|          | 3-(28)      | $H-S-\underset{Me}{\underset{ }{CH}}-CH_2-$         | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
| 30       | 3-(29)      | $H-S-CH_2-\underset{\text{Me}}{\underset{ }{CH}}$   | R      | -COOH | m      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
|          | 3-(30)      | $H-S-(CH_2)_3-$                                     | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
| 35       | 3-(31)      | $H-S-(CH_2)_2-\underset{Me}{\underset{ }{CH}}$      | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |
|          | 3-(32)      | $H-S-(CH_2)_2-\underset{Me}{\underset{ }{CH}}$      | R      | -COOH | p      | -Me    | -Me | S      | $-CH_2-$ | $-CH_2-$ |




| Compound | $R^1-S-A^1-$                                       | (a) $-R^2$ | (b) $-R^3$ | $-R^4$ | Z   | $-A^2-$ | $-A^3-$               |
|----------|--|------------|------------|--------|-----|---------|-----------------------|
| 4 - ①    | $H-S-CH_2-\underset{\text{Me}}{\underset{  }{CH}}$ | RS -COOH   | P          | -Me    | -Me | O       | $-CH_2-$ $-CH_2-$     |
| 4 - 2    | $H-S-CH_2-$  | RS -COOH   | P          | -Me    | -Me | O       | $-CH_2-$ $-CH_2-$     |
| 4 - 3    | $H-S-(CH_2)_2-$                                    | RS -COOH   | P          | -Me    | -Me | O       | $-CH_2-$ $-CH_2-$     |
| 4 - 4    | $H-S-(CH_2)_5-$                                    | RS -COOH   | P          | -Me    | -Me | O       | $-CH_2-$ $-CH_2-$     |
| 4 - 5    | $H-S-CH_2-\underset{\text{Me}}{\underset{  }{CH}}$ | RS -COOH   | P          | -Me    | -Et | O       | $-CH_2-$ $-CH_2-$     |
| 4 - 6    | $H-S-CH_2-\underset{\text{Me}}{\underset{  }{CH}}$ | RS -COOH   | P          | -Et    | -Et | O       | $-CH_2-$ $-CH_2-$     |
| 4 - 7    | $H-S-CH_2-\underset{\text{Me}}{\underset{  }{CH}}$ | RS -COOH   | P          | -Me    | -Me | O       | $-(CH_2)_2-$ $-CH_2-$ |
| 4 - 8    | $H-S-CH_2-\underset{\text{Me}}{\underset{  }{CH}}$ | RS -COOH   | P          | -Me    | -Me | O       | $-(CH_2)_4-$ $-CH_2-$ |
| 4 - 9    | $H-S-CH_2-CMe_2$                                   | RS -COOH   | P          | -Me    | -Me | O       | $-CH_2-$ $-CH_2-$     |
| 4 - 10   | $H-S-CH_2-CMe_2$                                   | RS -COOH   | P          | -Me    | -Et | O       | $-CH_2-$ $-CH_2-$     |
| 4 - 11   | $H-S-CH_2-CMe_2$                                   | RS -COOH   | P          | -Et    | -Et | O       | $-CH_2-$ $-CH_2-$     |
| 4 - 12   | $H-S-CH_2-CMe_2$                                   | RS -COOH   | P          | -Me    | -Me | O       | $-(CH_2)_2-$ $-CH_2-$ |
| 4 - 13   | $H-S-CH_2-CMe_2$                                   | RS -COOH   | P          | -Me    | -Me | O       | $-(CH_2)_4-$ $-CH_2-$ |
| 4 - 14   | $H-S-CH_2-\underset{\text{Me}}{\underset{  }{CH}}$ | RS -COOH   | m          | -Me    | -Me | O       | $-CH_2-$ $-CH_2-$     |



|    | Compound | R <sup>1</sup> -S-A <sup>1</sup> -                    | (a) -R <sup>2</sup> | (b) | -R <sup>3</sup> | -R <sup>4</sup> | Z | -A <sup>2</sup> -  | -A <sup>3</sup> -  |
|----|----------|---|---------------------|-----|-----------------|-----------------|---|--------------------|--------------------|
| 5  | 5 - (1)  | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me                | R -CONHMe           | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |
|    | 5 - 2    | PhCO-S-CH <sub>2</sub> -CH-<br> <br>Me                | R -CONHBzl          | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |
| 10 | 6 - (1)  | H-S-CH <sub>2</sub> -CH-<br> <br>Me                   | R -CONHMe           | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |
|    | 6 - 2    | H-S-CH <sub>2</sub> -CH-<br> <br>Me                   | R -CONHBzl          | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |
| 15 | 7 - (1)  | Me-S-CH <sub>2</sub> -CH-<br> <br>Me                  | R -COOH             | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |
|    | 7 - (2)  | Ph-CH <sub>2</sub> -S-CH <sub>2</sub> -CH-<br> <br>Me | R -COOH             | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |
| 20 | 8 - (1)  | H-S-CH <sub>2</sub> -CH-<br> <br>Me                   | R -COOEt            | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |
|    | 8 - 2    | H-S-CH <sub>2</sub> -CH-<br> <br>Me                   | R -COOBzl           | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |
| 25 | 8 - 3    | H-S-CH <sub>2</sub> -CMe <sub>2</sub> -               | R -COOEt            | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |
|    | 8 - 4    | H-S-CH <sub>2</sub> -CMe <sub>2</sub> -               | R -COOBzl           | p   | -Me             | -Me             | S | -CH <sub>2</sub> - | -CH <sub>2</sub> - |

## 35 Claims

1. A compound represented by the general formula [I] or a salt thereof,



wherein

R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group, a lower alkanoyl group or a benzoyl group, and each phenyl ring in the phenyl-lower alkyl group and the benzoyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group;

**R<sup>2</sup> represents a carboxyl group which can be converted into an ester, an amide or a hydroxamic acid;**

**R<sup>3</sup> represents a lower alkyl group;**

**R<sup>4</sup> represents a lower alkyl group;**

A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group, and the phenyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group;


A<sup>2</sup> represents a lower alkylene group;

A<sup>3</sup> represents a lower alkylene group; and  
 "Z" represents a sulfur atom or an oxygen atom.

2. A compound represented by the general formula [I] or a salt thereof,

5

10



15

wherein

20

25

30

R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group, a lower alkanoyl group or a benzoyl group, and each phenyl ring in the phenyl-lower alkyl group and the benzoyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group;

R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester or a phenyl-lower alkyl ester; a carboxyl group which can be converted into an amide with ammonia, a lower alkyl amine or a phenyl-lower alkyl amine; or a carboxyl group which can be converted into a hydroxamic acid, and each phenyl ring in the phenyl-lower alkyl ester and the phenyl-lower alkyl amine can be substituted by a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a lower alkylendioxy group, a nitro group, an amino group, a lower alkylamino group or a lower alkanoylamino group;

R<sup>3</sup> represents a lower alkyl group;

R<sup>4</sup> represents a lower alkyl group;

A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group, and the phenyl group can be substituted by a halogen atom, a lower alkyl group or a lower alkoxy group;

A<sup>2</sup> represents a lower alkylene group;


A<sup>3</sup> represents a lower alkylene group; and

"Z" represents a sulfur atom or an oxygen atom.

3. A compound represented by the general formula [I] or a salt thereof,

35

40



45

wherein

50

55

R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group;

R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester or a phenyl-lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkyl amine or a phenyl-lower alkyl amine;

R<sup>3</sup> represents a lower alkyl group;

R<sup>4</sup> represents a lower alkyl group;


A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group;

A<sup>2</sup> represents a lower alkylene group;

A<sup>3</sup> represents a lower alkylene group; and

"Z" represents a sulfur atom or an oxygen atom.

4. A compound represented by the general formula [I] or a salt thereof,




wherein

- $\text{R}^1$  represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group;  
 $\text{R}^2$  represents a carboxyl group which can be converted into a lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkyl amine;  
 $\text{R}^3$  represents a lower alkyl group;  
 $\text{R}^4$  represents a lower alkyl group;  
 $\text{A}^1$  represents a lower alkylene group which can be substituted by a phenyl group;  
 $\text{A}^2$  represents a lower alkylene group;  
 $\text{A}^3$  represents a lower alkylene group; and  
 $\text{Z}$  represents a sulfur atom or an oxygen atom.

5. The compound or a salt thereof as claimed in claim 4, wherein  $\text{R}^1$  represents a hydrogen atom, a methyl group, a benzyl group or a benzoyl group;  $\text{R}^2$  represents a carboxyl group which can be converted into an ethyl ester; or a carboxyl group which can be converted into an amide with methylamine;  $\text{R}^3$  represents a methyl group or an ethyl group;  $\text{R}^4$  represents a methyl group or an ethyl group;  $\text{A}^1$  represents a methylene group, a methylmethylenegroup, an ethylene group, a propylene group, an ethylethylenegroup, a propylethylenegroup, an isopropylethylenegroup, a benzylethylenegroup, a phenylethylenegroup, a trimethylenegroup or a methyltrimethylenegroup;  $\text{A}^2$  represents a methylene group or an ethylene group; and  $\text{A}^3$  represents a methylene group.

6. A compound represented by the general formula [I] or a salt thereof,



wherein

- $\text{R}^1$  represents a hydrogen atom;  
 $\text{R}^2$  represents a carboxyl group which can be converted into a lower alkyl ester;  
 $\text{R}^3$  represents a lower alkyl group;  
 $\text{R}^4$  represents a lower alkyl group;  
 $\text{A}^1$  represents a lower alkylene group which can be substituted by a phenyl group;  
 $\text{A}^2$  represents a lower alkylene group;  
 $\text{A}^3$  represents a lower alkylene group; and  
 $\text{Z}$  represents a sulfur atom.

7. The compound or a salt thereof as claimed in claim 6, wherein  $\text{R}^2$  represents a carboxyl group which can be converted into an ethyl ester;  $\text{R}^3$  represents a methyl group or an ethyl group;  $\text{R}^4$  represents a methyl group or an ethyl group;  $\text{A}^1$  represents a methylene group, an ethylene group, a propylene group, an ethylethylenegroup, a propylethylenegroup, an isopropylethylenegroup or a phenylethylenegroup;  $\text{A}^2$  represents a methylene group; and  $\text{A}^3$  represents a methylene group.

8. The compound or a salt thereof as claimed in claim 2, wherein R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group.
9. The compound or a salt thereof as claimed in claim 2, wherein R<sup>1</sup> represents a hydrogen atom, a methyl group, a benzyl group or a benzoyl group.
10. The compound or a salt thereof as claimed in claim 2, wherein R<sup>1</sup> represents a hydrogen atom.
11. The compound or a salt thereof as claimed in claim 2, wherein R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester or a phenyl-lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine or a phenyl-lower alkylamine.
12. The compound or a salt thereof as claimed in claim 2, wherein R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine.
13. The compound or a salt thereof as claimed in claim 2, wherein R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester; or a carboxyl group which can be converted into an amide with methylamine.
14. The compound or a salt thereof as claimed in claim 2, wherein R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester.
15. The compound or a salt thereof as claimed in claim 2, wherein R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester.
16. The compound or a salt thereof as claimed in claim 2, wherein R<sup>3</sup> represents a methyl group or an ethyl group.
17. The compound or a salt thereof as claimed in claim 2, wherein R<sup>4</sup> represents a methyl group or an ethyl group.
18. The compound or a salt thereof as claimed in claim 2, wherein A<sup>1</sup> represents a lower alkylene group which can be substituted by a phenyl group.
19. The compound or a salt thereof as claimed in claim 2, wherein A<sup>1</sup> represents a methylene group, a methylenemethylene group, an ethylene group, a propylene group, an ethylethylene group, a propylethylene group, an isopropylethylene group, a benzylethylene group, a phenylethylene group, a trimethylene group or a methyltrimethylene group.
20. The compound or a salt thereof as claimed in claim 2, wherein A<sup>1</sup> represents a methylene group, an ethylene group, a propylene group, an ethylethylene group, a propylethylene group, an isopropylethylene group or a phenylethylene group.
21. The compound or a salt thereof as claimed in claim 2, wherein Z represents a sulfur atom.
22. The compound or a salt thereof as claimed in claim 2, wherein R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group; and R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester or a phenyl-lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine or a phenyl-lower alkylamine.
23. The compound or a salt thereof as claimed in claim 2, wherein R<sup>1</sup> represents a hydrogen atom, a lower alkyl group, a phenyl-lower alkyl group or a benzoyl group; and R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester; or a carboxyl group which can be converted into an amide with a lower alkylamine.
24. The compound or a salt thereof as claimed in claim 2, wherein R<sup>1</sup> represents a hydrogen atom, a methyl group, a benzyl group or a benzoyl group; and R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester; or a carboxyl group which can be converted into an amide with methylamine.
25. The compound or a salt thereof as claimed in claim 2, wherein R<sup>1</sup> represents a hydrogen atom; R<sup>2</sup> represents a carboxyl group which can be converted into a lower alkyl ester; and "Z" represents a sulfur atom.

26. The compound or a salt thereof as claimed in claim 2, wherein R<sup>1</sup> represents a hydrogen atom; R<sup>2</sup> represents a carboxyl group which can be converted into an ethyl ester; and "Z" represents a sulfur atom.
27. 3-[4-(N, N-Dimethylamino)benzylthio]-2-(3-mercapto-2-methylpropionylamino)propionic acid or a salt thereof.
- 5 28. (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-methylpropionylamino]propionic acid or a salt thereof.
- 10 29. (2R)-3-[4-(N, N-Dimethylamino)benzylthio]-2-[(2S)-3-mercapto-2-propylpropionylamino]propionic acid or a salt thereof.
30. A pharmaceutical composition comprising the compound or a salt thereof as claimed in claims 1 to 29 as an active ingredient.
- 15 31. A leukotriene A<sub>4</sub> inhibitor comprising the compound or a salt thereof as claimed in claims 1 to 29 as an active ingredient.
32. A therapeutic agent for inflammatory diseases comprising the compound or a salt thereof as claimed in claims 1 to 29 as an active ingredient.
- 20 33. An antirheumatic agent comprising the compound or a salt thereof as claimed in claims 1 to 29 as an active ingredient.

25

30

35

40

45

50

55

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP96/00521

## A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl<sup>6</sup> C07C323/59, 323/60, 327/32, A61K31/16, 31/19, 31/22

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. Cl<sup>6</sup> C07C323/50-323/63, 327/32, A61K31/16, 31/19, 31/22

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages   | Relevant to claim No. |
|-----------|--|-----------------------|
| A         | JP, 2-776, A (Santen Pharmaceutical Co., Ltd.),<br>January 5, 1990 (05. 01. 90),<br>Claim & EP, 326326, A1 & US, 5292926, A          | 1 - 33                |
| A         | JP, 2-503799, A (Schering Corp.),<br>November 8, 1990 (08. 11. 90),<br>Claim & EP, 322633, A1 & WO, 89/05796, A1<br>& US, 5061710, A | 1 - 33                |

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

May 15, 1996 (15. 05. 96)

Date of mailing of the international search report

June 4, 1996 (04. 06. 96)

Name and mailing address of the ISA/

Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**